WO1998010088A1 - An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase - Google Patents
An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase Download PDFInfo
- Publication number
- WO1998010088A1 WO1998010088A1 PCT/US1997/015716 US9715716W WO9810088A1 WO 1998010088 A1 WO1998010088 A1 WO 1998010088A1 US 9715716 W US9715716 W US 9715716W WO 9810088 A1 WO9810088 A1 WO 9810088A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aav
- host cell
- vector
- recombinant
- rep
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- Adeno-associated virus is a replication- deficient parvovirus, the genome of which is about 4.6 kb in length, including 145 nucleotide inverted terminal repeats (ITRs) .
- the single-stranded DNA genome of AAV contains genes responsible for replication (rep) and formation of virions (cap) .
- rep nucleotide inverted terminal repeats
- cap nucleotide inverted terminal repeats
- AAV possesses unique features that make it attractive as a vector for delivering foreign DNA to cells.
- Various groups have studied the potential use of AAV in the treatment of disease states.
- T7 RNA polymerase is the product of T7 gene 1, which can recognize its responsive promoter sequence specifically and exhibit a high transcriptase activity [M. Chamberlin et al, Nature - ££8_:227-231 (1970); J. Dunn and F. Studier, J. Mol.
- the present invention provides an inducible method for efficient production of rAAV which makes use of T7 polymerase.
- T7 Pol is derived from lambda phage and its promoter is not active in mammalian cells.
- expression of rep/cap can be controlled by placing these genes under control of the T7 promoter and providing the T7 Pol in trans or under the control of an inducible promoter.
- This method avoids the toxic effects of rep which rendered prior art methods of producing rAAV inefficient.
- the method of the invention is particularly suitable for large scale production of rAAV, which is desired for rAAV vectors to be used in gene therapy.
- the invention provides a method of producing rAAV which utilizes three vectors.
- a first vector is capable of expressing T7 polymerase in the host cell following transfection or infection.
- a second vector comprises the AAV rep and cap genes under the control of T7 promoter sequences (T7/rep/cap) .
- the third vector comprises a cassette containing 5 • and 3 ' AAV inverted terminal repeats (ITRs) flanking a selected transgene.
- ITRs inverted terminal repeats
- the invention provides a method in which a host cell is stably transfected with one of the three components of the system used in the triple infection system. The remaining components are introduced into the host cell, as described above.
- the invention provides method in which a vector containing T7 /rep /cap and a vector containing a cassette comprising a selected minigene flanked by 5 1 and 3' AAV ITRs are introduced into a host cell expressing T7 polymerase. The host cell is then cultured under conditions which permit production of rAAV.
- this invention provides a method which utilizes a host cell stably transfected with a plasmid containing T7 /rep/cap.
- a vector containing T7 pol and a vector containing a cassette comprising 5' AAV inverse terminal repeat (ITR), a selected minigene, and 3' AAV ITR are introduced into the host cell.
- the host cell is cultured under conditions which permit production of rAAV.
- the invention provides a method which utilizes a host cell stably transfected with a rescuable rAAV cassette.
- a vector containing T7 pol and a vector containing T7 /rep/ cap are introduced into the host cell.
- the host cell is cultured under conditions which permit production of rAAV.
- the present invention provides a method which utilizes a host cell stably transfected with two of the three components of the system used in the triple infection system. The remaining component is then introduced into the host cell, as described above.
- the present invention provides a method which utilizes a host cell stably transfected with the three components of the system used in the triple infection system.
- the T7 Pol is controlled by an inducible promoter.
- the invention provides a rAAV produced according to the method of the invention.
- Fig. 1 provides a schematic illustration of the construction of a recombinant adenovirus containing the T7 polymerase gene.
- Fig. 2 provides a schematic illustration of the construction of a recombinant plasmid containing the AAV rep/cap genes under control of a T7 promoter.
- Fig. 3 provides a schematic illustration of the construction of a recombinant adenovirus containing the rep/cap genes under control of a T7 promoter.
- Fig. 4 provides a schematic illustration of the construction of a recombinant hybrid Ad/AAV virus.
- the invention provides an inducible method for efficient production of recombinant AAV vectors useful particularly for gene delivery and transfer. Specifically, the invention provides methods of AAV production in which expression of the toxic but necessary rep gene is controlled by the T7 promoter.
- the method of the invention for production of rAAV involves introducing into a host cell the AAV rep and cap genes under control of a T7 promoter, and a recombinant adeno-associated virus (rAAV) cassette containing a selected minigene flanked by AAV ITRs.
- rAAV adeno-associated virus
- Upon introduction of a gene encoding T7 pol high level expression of rep protein from the T7/rep/cap construct is induced and cells may be grown on a large scale.
- the cells are caused to express the T7 polymerase which acts on the T7 promoter. This facilitates the efficient replication and packaging of rAAV carrying a gene of interest.
- a host cell may be triple transfected (or infected) with vectors containing the above elements.
- a host cell which expresses one or more of the required elements and may be transfected/infected with the remaining elements is utilized.
- a host cell which stably expresses all three elements of the system, and the T7 pol is placed under the control of an inducible promoter, which permits rep/cap expression to be controlled and the avoidance of toxic effects to the cell.
- adenoviral constructs are currently preferred.
- a different viral (adenoviral or non-adenoviral) or a plasmid vector which is capable of driving expression of the desired genes in the host cell.
- vectors carrying the required elements of this system e.g., the T7 polymerase, may be readily constructed using retroviruses. Therefore, this invention is not limited by the virus or plasmid selected for purposes of introducing the T7 pol, T7/rep/cap, or AAV cassette into the host cell.
- At least one of the vectors is a virus which provides the necessary helper functions to enable packaging.
- the helper functions may be provided by a co-transfected adenovirus or herpesvirus. Suitable techniques for introducing these vectors into the host cell are discussed below and are known to those of skill in the art.
- a "host cell” is any cell (cell line) , preferably mammalian, which permits expression of the T7 pol and T7/rep/cap and packaging of the rAAV containing the cassette, under the conditions described herein. Suitable packaging cells are known, and may be readily selected by the skilled artisan.
- a host cell used for assembly and packaging of recombinant AAV may be transfected with plasmid vectors or infected with viral vectors containing the required components of the system.
- a first vector contains the T7 Pol gene under the control of a suitable promoter.
- the nuclear localized T7 Pol gene is obtained from a publicly available plasmid [M. Strauss, Nucleic Acid Res.. 12:8485-8493 (1989)]. However, the gene may alternatively be obtained from other commercial and academic sources, including the American Type Culture Collection (pTF7-3, Accession No. 484944). See, also GenBank accession number M30308. Desirably, the T7 pol gene is linked to a nuclear localization signal, such as that described in Dunn, Gene. 6JJ:259-266 (1988), using conventional techniques.
- T7 Pol is under the control of a cytomegalovirus (CMV) immediate early promoter/enhancer [see, e.g., Boshart et al, Cell. 41:521-530 (1985)].
- CMV cytomegalovirus
- suitable promoters may be readily selected by one of skill in the art.
- Useful promoters may be constitutive promoters or regulated (inducible) promoters, which will enable control of the amount of the transgene to be expressed.
- another suitable promoter includes, without limitation, the Rous sarcoma virus LTR promoter/enhancer.
- Still other promoter/enhancer sequences may be selected by one of skill in the art.
- the vector also includes other conventional regulatory elements necessary to drive expression of T7 Pol in a cell transfected with the vector.
- regulatory elements are known to those of skill in the art.
- the second vector component of this system contains the rep and cap genes under control of a T7 promoter.
- the rep and cap genes can be obtained from a variety of known sources. See, e.g., T. Shenk, J. Virol.. 61:3096-3101 (1987), which provides the AAV2 genome within the plasmid psub20l; E. W. Lusby et al, J. Virol. , 4_l: 518-526 (1982) and J. Smuda and B.J. Carter, Virology. 1 :310-318 (1991).
- T7 promoter sequences can be obtained from a variety of known sources. See, e.g., T. Shenk, J. Virol.. 61:3096-3101 (1987), which provides the AAV2 genome within the plasmid psub20l; E. W. Lusby et al, J. Virol. , 4_l: 518-526 (1982) and J. Smuda and B.J. Carter,
- the vector further contains the sequence of untranslated region (UTR) of encephalomyocarditis (EMCV) downstream of the T7 promoter.
- UTR untranslated region
- EMCV encephalomyocarditis
- the vector also includes conventional regulatory elements necessary to drive expression of the rep/cap in a cell transfected with the vector.
- regulatory elements are known to those of skill in the art.
- the third vector component contains a rAAV cassette containing a minigene flanked by AAV ITRs.
- a minigene contains a suitable transgene, a promoter, and other regulatory elements necessary for expression of the transgene.
- the AAV sequences employed are preferably limited to the cis-acting 5 ' and 3 ' inverted terminal repeat (ITR) sequences [See, e.g., B. J. Carter, in "Handbook of Parvoviruses" , ed. , P. Tijsser, CRC Press, pp.155-168 (1990)]. Desirably, substantially the entire 143 bp sequences encoding the ITRs are used in the vectors.
- AAV ITR sequences may be obtained from any known AAV, including presently identified human AAV types. Similarly, AAVs known to infect other animals may also be employed in the vector constructs of this invention. The selection of the AAV is not anticipated to limit the following invention.
- a variety of AAV strains, types 1-4, are available from the American Type Culture Collection or available by request from a variety of commercial and institutional sources. In the following exemplary embodiment an AAV-2 is used for convenience.
- the 5 • and 3 • AAV ITR sequences flank a minigene which is made up of a selected transgene sequence and associated regulatory elements.
- the transgene sequence of the vector is a nucleic acid sequence heterologous to the AAV sequence, which encodes a polypeptide or protein of interest.
- the transgene is operatively linked to regulatory components in a manner which permits transgene transcription.
- transgene sequence will depend upon the use to which the resulting vector will be put.
- one type of transgene sequence includes a reporter sequence, which upon expression produces a detectable signal.
- reporter sequences include without limitation an E. coli beta- galactosidase (LacZ) cDNA, an alkaline phosphatase gene and a green fluorescent protein gene. These sequences, when associated with regulatory elements which drive their expression, provide signals detectable by conventional means, e.g., ultraviolet wavelength absorbance, visible color change, etc.
- a more preferred transgene sequence includes a therapeutic gene which expresses a desired gene product in a host cell.
- These therapeutic nucleic acid sequences typically encode products which may be administered to a patient in vivo or ex vivo to replace or correct an inherited or non- inherited genetic defect or treat an epigenetic disorder or disease.
- the selection of the transgene sequence is not a limitation of this invention.
- the minigene also includes conventional regulatory elements necessary to drive expression of the transgene in a cell transfected with the vector carrying the AAV cassette.
- the minigene contains a selected promoter which is linked to the transgene and located within the minigene, between the AAV ITR sequences of the vector.
- promoter which mediates expression of the transgene is a routine matter and is not a limitation of the vector.
- Useful promoters include those which are discussed above in connection with the first vector component.
- the minigene will also desirably contain heterologous nucleic acid sequences including sequences providing signals required for efficient polyadenylation of the transcript and introns with functional splice donor and acceptor sites.
- a common poly-A sequence which is employed in the exemplary vectors of this invention is that derived from the papovavirus SV-40. The poly-A sequence generally is inserted following the transgene sequences and before the 3* AAV ITR sequence.
- a common intron sequence is also derived from SV-40, and is referred to as the SV-40 T intron sequence.
- a minigene of the present invention may also contain such an intron, desirably located between the promoter/enhancer sequence and the transgene. Selection of these and other common vector elements are conventional and many such sequences are available [see, e.g., Sambrook et al, and references cited therein].
- the rAAV vector containing the AAV ITRs flanking the minigene may be carried on a plasmid backbone and used to transfect a selected host cell or may be flanked by viral sequences (e.g., adenoviral sequences) which permit it to infect the selected host cell.
- viral sequences e.g., adenoviral sequences
- Suitable Ad/AAV recombinant viruses may be produced in accordance with known techniques. See, e.g., WO 96/13598, WO 95/23867, and WO 95/06743, which are incorporated by reference herein.
- a cell line stably transfected with T7 rep/cap may be double transfected (infected) with a vector carrying T7 pol and a vector carrying the rAAV cassette, as illustrated in the following table.
- a cell line which contains a rescuable rAAV cassette may be double transfected (infected) with a vector containing T7 Pol and a vector containing T7/rep/cap, as illustrated in the following table.
- a stable cell line of the invention can be produced by transfection of a desired cell, e.g., 293 cells or other packaging cell lines expressing required adenoviral genes, with a plasmid containing the desired gene, e.g., T7 Pol, using conventional techniques and selected via an accompanying resistant marker gene. Depending upon whether inducible or constitutive expression is desired, an appropriate promoter may be selected.
- the cell may be transfected with a plasmid containing T7 Pol under control of a metallothionein promoter.
- a host cell constitutively expressing T7 Pol it may be inserted under control of a RSV or CMV promoter. Similar techniques may be used for providing a host cell containing the T7/rep/cap and a host cell containing a rescuable rAAV. The examples below describe production of stable cell lines. However, one of skill in the art could readily produce such cell lines using other conventional techniques. See, generally, Ausubel et al, Current Protocols in Molecular Biology (Wiley Interscience 1987) .
- a cell line which stably expresses two of the components of this system may be constructed, and then transfected (or infected) with a vector containing the remaining component of the system, as described above.
- a cell line is utilized which is stably transfected with the T7/rep/cap and a rescuable rAAV.
- the cell line is then transfected or infected with a vector containing the T7 pol.
- the cell line is stably transfected with the T7 pol and a rescuable rAAV.
- the cell line is then transfected or infected with a vector containing the T7 rep/cap.
- a cell line which stably expresses all three of the components of this system may be constructed and utilized in the method of the invention.
- a suitable packaging cell line is constructed which contains the rAAV, the T7/rep/cap and the T7 pol.
- the T7 Pol is placed under the control of an inducible promoter. Suitable inducible promoters are known to those of skill in the art and are discussed herein.
- T7 Pol may be placed under control of a metallothionein promoter. In this manner, expression of the T7 Pol, and thus the rep/cap, which are under control of the T7 promoter can be regulated and toxic effects to the cell avoided.
- Assembly of the selected DNA sequences of the adenovirus, AAV and the reporter genes or therapeutic genes and other vector elements into the vectors described above utilize conventional techniques.
- Such techniques include cDNA cloning such as those described in texts [Sambrook et al, cited above], use of overlapping oligonucleotide sequences of the adenovirus or AAV genome, polymerase chain reaction, and any suitable method which provides the desired nucleotide sequence.
- HEK human embryonic kidney
- Other conventional methods employed in this invention include homologous recombination of the viral genomes, plaquing of viruses in agar overlay, methods of measuring signal generation, and the like.
- the host cell Following infection/transfection, the host cell is then cultured under standard conditions, to enable production of the rAAV. See, e.g., F. L. Graham and L. Prevec, Methods Mol. Biol.. 7:109-128 (1991). Desirably, once the rAAV is identified using conventional techniques, it may be isolated using standard techniques and purified.
- Figure 1 provides a schematic of the construction of the recombinant adenovirus carrying the T7 polymerase.
- pMTT7N The plasmid pMTT7N was obtained from Dr. Michael Strauss [A. Lieber et al, Nucl. Acids Res.. 12:8485-8493 (1989)].
- pMTT7N contains a N-terminal nuclear location signal of SV40 large T antigen fused to the T7 Pol gene (T7N Pol) which is linked to the polyadenylation sequence of SV40. Expression is driven by the inducible mouse metallothionein promoter.
- the pMTT7N plasmid DNA was digested with Bglll and PvuII restriction enzymes and the fragments separated on an agarose gel.
- pAd.CMV.link.l is a plasmid containing the adenoviral sequences 0 to 16 map units deleted of Ela and Elb into which a CMV promoter-polylinker cassette was cloned. This is described in X. Ye et al, J. Biol. Chem.. 271:3639-3646 (1996).
- the expression unit of T7 Pol is directed by the CMV promoter.
- the promoter for the T7 Pol gene is linked to a PolyA tail as a cassette within the sequence of adenovirus 0-1 map unit (mu) and 9-16 mu.
- the pAd.CMV.T7N is linearized by Nhe I digestion and co- transfected with Cla I linearized Addel327 backbone using Cellphate kit (Pharmacia) . Approximately 1 week post- transfection, the T7 Pol adenovirus can be isolated from the plaques for further purification.
- a cell line stably expressing T7 Pol is established by co-transfection of plasmids pMTT7N and pMTCB6+ (which provides a selective marker) [K. H. Choo et al, SNA, 5:529-538; Eur. J. Biochem.. 124:417-424] into 293 cell at a ratio of 10:1 using calcium phosphate precipitation [F. Graham and A. van der Eb, Virol.. 5_2:456-467 (1973)].
- Colony cloning is carried out by Geneticin selection at a concentration of 1 mg/ml. Each clone obtained is transfected with pT7 rep/cap plasmid [see. Example 3 below] and analyzed for its ability to induce the expression of Rep protein upon induction by supplementation with Zn ++ .
- the T7N Pol obtained by Bglll/PvuII digestion of pMTT7N, as described above was subcloned downstream of RSV promoter at the cloning sites of BamHI and PvuII in the vector of pEBVhis [Invitrogen] .
- the resulting plasmid, designated pEBVhisT7N was transfected into 293 cells and selected with Hygromycin at a concentration of 400 ⁇ g/ml. Each positive clone is analyzed for the presence of T7 Pol by its ability to produce expression of T7-LacZ or T7- rep/cap in cells transfected with these plasmids.
- the plasmid pTMl [B. Moss et al, Nature. 348:91-92 (1990)], designed for expressing genes under control of the T7 promoter/EMCV UTR (untranslated region of encephalomyocarditis) , was used as the vector for expressing AAV rep/cap.
- the entire coding sequence of rep/cap was separated into two portions by the unique Sad site and subcloned into the pTMl plasmid as described below.
- N-rep the left end of the rep sequence (N-rep) was first amplified by PCR.
- the sequence of the upper primer was SEQ ID NO: 2: TATTTAAGCCCGAGTGAGCT. (from position of 255 to 274) which introduced a nucleotide substitution A->T at position 274 (underlined) .
- a Sad site was then generated to permit the cloning of N-rep into pTMl and in-frame expression of Rep protein from the EMCV UTR preferred initiation site (within the Ncol site) .
- the PCR product (739 bp in length) was directly cloned into pCR2.1 vector (Invitrogen) and named pCR-N-rep.
- the pTM-1 plasmid was digested with Sad and Stu I restriction enzymes and ligated with a 3.7 kb SacI/SnaBI fragment from psub201 [Samulski et al, J. Virol. ⁇ .51:3096-3101 (1987)] containing the right end of the AAV genome (without ITR sequence), i.e., the c- terminal portion of rep and full-length cap sequence.
- This T7 promoter-driven rep/cap construct is named pT7-c- rep/cap.
- the first 535 bp sequence of rep was removed from the pCR-N-Rep plasmid by Sad digestion and subcloned into pT7-C-rep/cap, which has similarly been digested with Sad and subjected to alkaline phosphatase treatment to prevent self-ligation of the vector.
- the final construct was named pT7 rep/cap which contains the full length coding sequence of rep/cap downstream of T7 promoter/EMCV UTR, followed by the T7 terminating sequence.
- Adenovirus pAd.link is a construct similar to pAd.CMV. link, a plasmid containing the adenoviral sequences 0 to 16 map units deleted of Ela and Elb as described in the other adenovirus vectors into which a CMV promoter-polylinker cassette was cloned and described in X. Ye et al, J. Biol. Chem.. 221:3639-3646 (1996). However, pAd.link contains no CMV promoter or polyA tail sequence.
- the entire region including the T7 promoter, EMCV UTR, rep/cap and T7 terminating sequence was excised from pT7 rep/cap by digestion with Clal and EagI, and then subcloned into the adenoviral sequences of pAd.link, which had previously been subjected to Clal/Sail digestion, after filling in the sticky ends of EagI and Sail by Klenow polymerase.
- the resulting plasmid is designated pAd.T7 rep/cap.
- the pAd.T7 rep/cap is co-transfected with the Clal linearized Ad.del327 backbone DNA into 293 cell for the generation of T7 rep/cap adenovirus.
- Example 4 - Cell Line Expressing rep/cap
- a cell line stably transfected with pT7 rep/cap is established by transfection of pMTCB6+ into 293 cell at ratio of 10:1 and selected with Geneticin. Each clone is analyzed for the presence of rep protein by transfection with T7 Pol expressing plasmid.
- Example 5 Production of Recombinant AAV Hybrid Vector Plasmid pAV.CMVLacZ serves as a template for rAAV to be replicated and packaged in the presence of AAV non-structural and capsid proteins.
- Plasmid AV.CMVLacZ is a rAAV cassette in which rep and cap genes are replaced with a minigene expressing ⁇ -galactosidase from a CMV promoter.
- the linear arrangement of AV.CMV acZ includes: (a) the 5 1 AAV ITR (bp 1-173) obtained by PCR using pAV2 [C. A. Laughlin et al, Gene. 23: 65-73 (1983)] as template [nucleotide numbers 365-538 of SEQ ID NO:l];
- E. coli beta-galactosidase cDNA (nucleotide numbers 1356 - 4827 of SEQ ID N0:1), (e) an SV40 polyadenylation signal (a 237
- Bglll fragment (nucleotide numbers 5053 - 5221 of SEQ ID N0:l) .
- the LacZ gene can be replaced with a desired therapeutic or other transgene for the purpose of generating new rAAV. See, Fig. 4.
- the sequence including CMV directed LacZ reporter cassette in between two AAV ITR sequences is excised from pAV.CMV.LacZ by PvuII digestion. This fragment is ligated with the EcoRV treated pAd.link to generate the plasmid pAd.AV.CMVLacZ.
- This plasmid is co-transfected with Clal linearized Addel327 backbone DNA to generate an adeno-rAAV hybrid virus.
- Example 6 Cell line containing rescuable. integrated rAAV template
- 293 cells are transfected/infected with pAV.CMVLacZ/rAAV Ad hybrid virus to generate cell line that has incorporated rAAV, as determined by analysis of the geno ic DNA by Southern blot. The clone is examined for the rescue of rAAV template by transfection/infection with rep/cap expressing constructs.
- CAAATCAAAG AACTGCTCCT CAGTGGATGT TGCCTTTACT TCTAGGCCTG TACGGAAGTG 1320
- TCCAGTTCCG TTTATCCGGG CAAACCATCG AAGTGACCAG CGAATACCTG TTCCGTCATA 3420
- AAACCTTATT TATCAGCCGG AAAACCTACC GGATTGATGG TAGTGGTCAA ATGGCGATTA 4080
- CTTCTCGCTT CCGGCGGCAT CGGGATGCCC GCGTTGCAGG CCATGCTGTC CAGGCAGGTA 8100
- AAACTCTCAA GGATCTTACC GCTGTTGAGA TCCAGTTCGA TGTAACCCAC TCGTGCACCC 10080
- CAAAATGCCG CAAAAAAGGG AATAAGGGCG ACACGGAAAT GTTGAATACT CATACTCTTC 10200
- MOLECULE TYPE other nucleic acid
- SEQUENCE DESCRIPTION SEQ ID NO:2: TATTTAAGCC CGAGTGAGCT 20
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10512963A JP2001500015A (en) | 1996-09-06 | 1997-09-04 | Method for producing inducible recombinant adeno-associated virus using T7 polymerase |
EP97939829A EP0931158A1 (en) | 1996-09-06 | 1997-09-04 | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
IL12878097A IL128780A0 (en) | 1996-09-06 | 1997-09-04 | An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase |
CA002264482A CA2264482A1 (en) | 1996-09-06 | 1997-09-04 | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
AU41833/97A AU722624B2 (en) | 1996-09-06 | 1997-09-04 | An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2469996P | 1996-09-06 | 1996-09-06 | |
US60/024,699 | 1996-09-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998010088A1 true WO1998010088A1 (en) | 1998-03-12 |
Family
ID=21821933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/015716 WO1998010088A1 (en) | 1996-09-06 | 1997-09-04 | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0931158A1 (en) |
JP (1) | JP2001500015A (en) |
AU (1) | AU722624B2 (en) |
CA (1) | CA2264482A1 (en) |
IL (1) | IL128780A0 (en) |
WO (1) | WO1998010088A1 (en) |
Cited By (213)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000015821A1 (en) * | 1998-09-11 | 2000-03-23 | The Regents Of The University Of California | Recombinant adenovirus for tissue specific expression in heart |
US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
US6485966B2 (en) | 1999-03-18 | 2002-11-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
WO2003046124A2 (en) | 2001-11-21 | 2003-06-05 | The Trustees Of The University Of Pennsylvania | Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
WO2003078453A1 (en) | 2002-03-15 | 2003-09-25 | Wyeth Holdings Corporation | Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity |
US6759237B1 (en) | 1998-11-05 | 2004-07-06 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
US6793926B1 (en) | 1999-05-27 | 2004-09-21 | Genovo, Inc. | Methods for production of a recombinant adeno-associated virus |
US6893865B1 (en) | 1999-04-28 | 2005-05-17 | Targeted Genetics Corporation | Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles |
US6924128B2 (en) | 1994-12-06 | 2005-08-02 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant AAV vectors |
US6953690B1 (en) | 1998-03-20 | 2005-10-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
US6989264B2 (en) | 1997-09-05 | 2006-01-24 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US7115391B1 (en) | 1999-10-01 | 2006-10-03 | Genovo, Inc. | Production of recombinant AAV using adenovirus comprising AAV rep/cap genes |
US7198951B2 (en) | 2001-12-17 | 2007-04-03 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 9 sequences, vectors containing same, and uses therefor |
US7282199B2 (en) | 2001-12-17 | 2007-10-16 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
EP1925626A1 (en) | 2003-07-21 | 2008-05-28 | Transgene S.A. | Novel multifunctional cytokines |
EP1944043A1 (en) | 2001-11-21 | 2008-07-16 | The Trustees of the University of Pennsylvania | Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
EP2116605A2 (en) | 2004-06-17 | 2009-11-11 | Wyeth | Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV |
EP2123306A1 (en) | 2004-12-03 | 2009-11-25 | Fondazione Telethon | Use of a decoy protein that interferes with the hedgehog signalling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization |
WO2010051367A1 (en) | 2008-10-31 | 2010-05-06 | The Trustees Of The University Of Pennsylvania | Simian adenoviruses sadv-43, -45,-48,-49, and -50 and uses thereof |
WO2010138675A1 (en) | 2009-05-29 | 2010-12-02 | The Trustees Of The University Of Pennsylvania | Simian adenovirus 41 and uses thereof |
EP2292780A2 (en) | 2003-09-30 | 2011-03-09 | The Trustees of the University of Pennsylvania | Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof |
WO2011053998A2 (en) * | 2009-11-02 | 2011-05-05 | The Salk Institute For Biological Studies | Targeting of modifying enzymes for protein evolution |
EP2325298A2 (en) | 2008-03-04 | 2011-05-25 | The Trustees of The University of Pennsylvania | Simian adenoviruses SAdV-36, -42.1, -42.2, AND -44 and uses thereof |
EP2338900A1 (en) | 2001-11-13 | 2011-06-29 | The Trustees of The University of Pennsylvania | A method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby |
EP2357010A1 (en) | 2005-04-07 | 2011-08-17 | The Trustees of The University of Pennsylvania | Method of increasing the function of an AAV vector |
WO2011133890A1 (en) | 2010-04-23 | 2011-10-27 | University Of Massachusetts | Cns targeting aav vectors and methods of use thereof |
WO2012040550A1 (en) | 2010-09-26 | 2012-03-29 | Da Yu Enterprises, L.L.C. | Method of recombinant macromolecular production |
WO2012071318A2 (en) | 2010-11-23 | 2012-05-31 | The Trustees Of The University Of Pennsylvania | Subfamily e simian adenoviruses a1321, a1325, a1295, a1309, a1316 and a1322 and uses thereof |
EP2463362A1 (en) | 2007-11-28 | 2012-06-13 | The Trustees of The University of Pennsylvania | Simian subfamily c adenovirus SAdv-31 and uses thereof |
WO2012076715A1 (en) | 2010-12-09 | 2012-06-14 | Institut Pasteur | Mgmt-based method for obtaining high yield of recombinant protein expression |
WO2012112832A1 (en) | 2011-02-17 | 2012-08-23 | The Trustees Of The University Of Pennsylvania | Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer |
US8303567B2 (en) | 2003-09-26 | 2012-11-06 | The Trustees Of The University Of Pennsylvania | Method for delivering a macromolecular complex to muscle cells |
WO2012156535A1 (en) | 2011-05-19 | 2012-11-22 | Fundación Progreso Y Salud | Highly inducible dual-promoter lentiviral tet-on system |
WO2013043720A1 (en) | 2011-09-20 | 2013-03-28 | The University Of North Carolina At Chapel Hill | Regulation of sodium channels by plunc proteins |
WO2013083847A2 (en) | 2011-12-09 | 2013-06-13 | Institut Pasteur | Multiplex immuno screening assay |
US8556842B2 (en) | 2004-09-30 | 2013-10-15 | The Trustees Of The University Of Pennsylvania | Perfusion circuit and use therein in targeted delivery of macromolecules |
WO2013158879A1 (en) | 2012-04-18 | 2013-10-24 | The Children's Hospital Of Philadelphia | Composition and methods for highly efficient gene transfer using aav capsid variants |
WO2013173702A2 (en) | 2012-05-18 | 2013-11-21 | The Trustees Of The University Of Pennsylvania | Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof |
US8632995B2 (en) | 2006-07-27 | 2014-01-21 | Wyeth Llc | High-cell density fed-batch fermentation process for producing recombinant protein |
WO2014066443A1 (en) | 2012-10-23 | 2014-05-01 | Emory University | Gm-csf and il-4 conjugates, compositions, and methods related thereto |
WO2014068072A1 (en) | 2012-10-31 | 2014-05-08 | Institut Gustave-Roussy | Identification, assessment and therapy of essential thrombocythemia with resistance to jak2 inhibitors |
WO2015164786A1 (en) | 2014-04-25 | 2015-10-29 | University Of Massachusetts | Recombinant aav vectors useful for reducing immunity against transgene products |
WO2015168666A2 (en) | 2014-05-02 | 2015-11-05 | Genzyme Corporation | Aav vectors for retinal and cns gene therapy |
WO2016054557A1 (en) | 2014-10-03 | 2016-04-07 | University Of Massachusetts | Novel high efficiency library-identified aav vectors |
WO2016065001A1 (en) | 2014-10-21 | 2016-04-28 | University Of Massachusetts | Recombinant aav variants and uses thereof |
WO2016122791A1 (en) | 2015-01-30 | 2016-08-04 | The Regents Of The University Of California | Spinal subpial gene delivery system |
WO2016130591A2 (en) | 2015-02-10 | 2016-08-18 | Genzyme Corporation | Enhanced delivery of viral particles to the striatum and cortex |
WO2016130589A2 (en) | 2015-02-10 | 2016-08-18 | Genzyme Corporation | VARIANT RNAi |
WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
WO2016145217A1 (en) | 2015-03-10 | 2016-09-15 | The Trustees Of Columbia University In The City Of New York | Recombinant glut1 adeno-associated viral vector constructs and related methods for restoring glut1 expression |
WO2016164609A2 (en) | 2015-04-08 | 2016-10-13 | Genzyme Corporation | Production of oversized adeno-associated vectors |
WO2016172155A1 (en) | 2015-04-23 | 2016-10-27 | University Of Massachusetts | Modulation of aav vector transgene expression |
WO2016186772A2 (en) | 2015-05-16 | 2016-11-24 | Genzyme Corporation | Gene editing of deep intronic mutations |
US9523084B2 (en) | 2012-11-08 | 2016-12-20 | Centre National De La Recherche Scientifique (Cnrs) | Phosphodeoxyribosyl transferase mutant enzymes and uses thereof |
WO2016210170A1 (en) | 2015-06-23 | 2016-12-29 | The Children's Hospital Of Philadelphia | Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues |
EP3128010A1 (en) | 2007-11-28 | 2017-02-08 | The Trustees Of The University Of Pennsylvania | Simian subfamily e adenoviruses sadv-30 and uses thereof |
WO2017070525A1 (en) | 2015-10-22 | 2017-04-27 | University Of Massachusetts | Methods and compositions for treating metabolic imbalance in neurodegenerative disease |
WO2017075335A1 (en) | 2015-10-28 | 2017-05-04 | Voyager Therapeutics, Inc. | Regulatable expression using adeno-associated virus (aav) |
WO2017096164A1 (en) | 2015-12-02 | 2017-06-08 | The Board Of Trustees Of The Leland Stanford Junior University | Novel recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism |
WO2017139643A1 (en) | 2016-02-12 | 2017-08-17 | University Of Massachusetts | Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization |
WO2017143100A1 (en) | 2016-02-16 | 2017-08-24 | The Board Of Trustees Of The Leland Stanford Junior University | Novel recombinant adeno-associated virus capsids resistant to pre-existing human neutralizing antibodies |
WO2017147128A1 (en) | 2016-02-22 | 2017-08-31 | The University Of North Carolina At Chapel Hill | Peptide inhibitors of calcium channels |
WO2017191147A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
WO2017194912A1 (en) | 2016-05-09 | 2017-11-16 | Cambridge Enterprise Limited | Treatment of complement-mediated disorders |
WO2017216301A1 (en) | 2016-06-16 | 2017-12-21 | Charité Berlin | Neuropeptide-expressing vectors and methods for the treatment of epilepsy |
WO2018002081A1 (en) | 2016-06-27 | 2018-01-04 | Aicuris Anti-Infective Cures Gmbh | Hcmv entry inhibitors |
WO2018009894A1 (en) | 2016-07-07 | 2018-01-11 | Iovance Biotherapeutics, Inc. | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof |
WO2018009553A1 (en) | 2016-07-05 | 2018-01-11 | University Of Massachusetts | Aav2-mediated gene delivery of sfasl as a neuroprotective therapy in glaucoma |
WO2018022608A2 (en) | 2016-07-26 | 2018-02-01 | Biomarin Pharmaceutical Inc. | Novel adeno-associated virus capsid proteins |
US9890365B2 (en) | 2014-03-09 | 2018-02-13 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency |
WO2018035059A1 (en) | 2016-08-15 | 2018-02-22 | Genzyme Corporation | Methods for detecting aav |
WO2018049261A1 (en) | 2016-09-09 | 2018-03-15 | Icellhealth Consulting Llc | Oncolytic virus expressing immune checkpoint modulators |
WO2018057855A1 (en) | 2016-09-22 | 2018-03-29 | University Of Massachusetts | Aav treatment of huntington's disease |
WO2018060288A1 (en) | 2016-09-29 | 2018-04-05 | Glaxosmithkline Biologicals S.A. | Compositions and methods of treatment of persistent hpv infection |
WO2018069316A2 (en) | 2016-10-10 | 2018-04-19 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
WO2018104911A1 (en) | 2016-12-09 | 2018-06-14 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides |
WO2018122088A1 (en) | 2016-12-28 | 2018-07-05 | Transgene Sa | Oncolytic viruses and therapeutic molecules |
WO2018204694A1 (en) | 2017-05-03 | 2018-11-08 | Biomarin Pharmaceutical Inc. | Improved lentiviruses for transduction of hematopoietic stem cells. |
US10137176B2 (en) | 2013-03-15 | 2018-11-27 | The Trustee Of The University Of Pennsylvania | Compositions and methods for treating MPSI |
WO2018232017A1 (en) | 2017-06-13 | 2018-12-20 | Flagship Pioneering, Inc. | Compositions comprising curons and uses thereof |
WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | Oncolytic viruses expressing agents targeting metabolic immune modulators |
WO2019028306A2 (en) | 2017-08-03 | 2019-02-07 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
WO2019060726A1 (en) | 2017-09-22 | 2019-03-28 | Genzyme Corporation | Variant rnai |
WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
WO2019079240A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
US10335466B2 (en) | 2014-11-05 | 2019-07-02 | Voyager Therapeutics, Inc. | AADC polynucleotides for the treatment of parkinson's disease |
WO2019173434A1 (en) | 2018-03-06 | 2019-09-12 | Voyager Therapeutics, Inc. | Insect cell manufactured partial self-complementary aav genomes |
US10415015B2 (en) | 2016-10-31 | 2019-09-17 | Iovance Biotherapeutics, Inc. | Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion |
EP3539568A1 (en) | 2011-11-22 | 2019-09-18 | The Children's Hospital of Philadelphia | Virus vectors for highly efficient transgene delivery |
WO2019191701A1 (en) | 2018-03-30 | 2019-10-03 | The Board Of Trustees Of Leland Stanford Junior University | Novel recombinant adeno-associated virus capsids with enhanced human pancreatic tropism |
EP3552615A1 (en) | 2014-07-16 | 2019-10-16 | Transgene SA | Oncolytic virus for expression of immune checkpoint modulators |
WO2019210137A1 (en) | 2018-04-27 | 2019-10-31 | Voyager Therapeutics, Inc. | Methods for measuring the potency of aadc viral vectors |
WO2019210269A1 (en) | 2018-04-27 | 2019-10-31 | University Of Massachusetts | Aav capsids identified by in vivo library selection |
WO2019217582A1 (en) | 2018-05-08 | 2019-11-14 | Rutgers, The State University Of New Jersey | Aav-compatible laminin-linker polymerization proteins |
WO2019222136A2 (en) | 2018-05-14 | 2019-11-21 | Biomarin Pharmaceutical Inc. | Novel liver targeting adeno-associated viral vectors |
WO2019222444A2 (en) | 2018-05-16 | 2019-11-21 | Voyager Therapeutics, Inc. | Directed evolution |
WO2019222328A1 (en) | 2018-05-15 | 2019-11-21 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of parkinson's disease |
WO2019222329A1 (en) | 2018-05-15 | 2019-11-21 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
WO2019222441A1 (en) | 2018-05-16 | 2019-11-21 | Voyager Therapeutics, Inc. | Aav serotypes for brain specific payload delivery |
WO2019239311A1 (en) | 2018-06-12 | 2019-12-19 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides |
WO2020010042A1 (en) | 2018-07-02 | 2020-01-09 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord |
WO2020023612A1 (en) | 2018-07-24 | 2020-01-30 | Voyager Therapeutics, Inc. | Systems and methods for producing gene therapy formulations |
WO2020028816A1 (en) | 2018-08-03 | 2020-02-06 | Genzyme Corporation | Variant rnai against alpha-synuclein |
US10570395B2 (en) | 2014-11-14 | 2020-02-25 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
EP3613440A1 (en) | 2013-07-22 | 2020-02-26 | The Children's Hospital of Philadelphia | Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues |
US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
US10584337B2 (en) | 2016-05-18 | 2020-03-10 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
US10597660B2 (en) | 2014-11-14 | 2020-03-24 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
WO2020072849A1 (en) | 2018-10-04 | 2020-04-09 | Voyager Therapeutics, Inc. | Methods for measuring the titer and potency of viral vector particles |
WO2020072683A1 (en) | 2018-10-02 | 2020-04-09 | Voyager Therapeutics, Inc. | Redirection of tropism of aav capsids |
WO2020077165A1 (en) | 2018-10-12 | 2020-04-16 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
WO2020086893A1 (en) | 2018-10-25 | 2020-04-30 | Regeneron Pharmaceuticals, Inc. | Methods for analysis of viral capsid protein composition |
WO2020112967A1 (en) | 2018-11-29 | 2020-06-04 | University Of Massachusetts | Modulation of sptlc1 via recombinant adeno-associated vectors |
WO2020136232A1 (en) | 2018-12-28 | 2020-07-02 | Transgene Sa | Immunosuppressive m2 protein |
WO2020150556A1 (en) | 2019-01-18 | 2020-07-23 | Voyager Therapeutics, Inc. | Methods and systems for producing aav particles |
WO2020172537A1 (en) | 2019-02-22 | 2020-08-27 | University Of Massachusetts | Oxr1 gene therapy |
WO2020191201A1 (en) | 2019-03-19 | 2020-09-24 | Massachusetts Institute Of Technology | Control of nitrogen fixation in rhizobia that associate with cereals |
WO2020223274A1 (en) | 2019-04-29 | 2020-11-05 | Voyager Therapeutics, Inc. | SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS |
WO2020227515A1 (en) | 2019-05-07 | 2020-11-12 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
WO2020232044A1 (en) | 2019-05-14 | 2020-11-19 | Biomarin Pharmaceutical Inc. | Methods of redosing gene therapy vectors |
WO2021021674A1 (en) | 2019-07-26 | 2021-02-04 | Akouos, Inc. | Methods of treating hearing loss using a secreted target protein |
US10919814B2 (en) | 2015-07-13 | 2021-02-16 | Pivot Bio, Inc. | Methods and compositions for improving plant traits |
US10920244B2 (en) | 2009-04-30 | 2021-02-16 | The Trustees Of The University Of Pennsylvania | Compositions for targeting conducting airway cells comprising adeno-associated virus constructs |
WO2021030125A1 (en) | 2019-08-09 | 2021-02-18 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
WO2021041485A1 (en) | 2019-08-26 | 2021-03-04 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
WO2021046155A1 (en) | 2019-09-03 | 2021-03-11 | Voyager Therapeutics, Inc. | Vectorized editing of nucleic acids to correct overt mutations |
WO2021050970A1 (en) | 2019-09-13 | 2021-03-18 | Rutgers, The State University Of New Jersey | Aav-compatible laminin-linker polymerization proteins |
WO2021062164A1 (en) | 2019-09-27 | 2021-04-01 | Biomarin Pharmaceutical Inc. | Characterization of gene therapy viral particles using size exclusion chromatography and multi-angle light scattering technologies |
US10973929B2 (en) | 2016-02-03 | 2021-04-13 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type I |
WO2021155137A1 (en) | 2020-01-29 | 2021-08-05 | Genzyme Corporation | Modified adeno-associated viral capsid proteins for ocular gene therapy and methods of use thereof |
WO2021168362A1 (en) | 2020-02-21 | 2021-08-26 | Akouos, Inc. | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
WO2021202494A1 (en) | 2020-03-31 | 2021-10-07 | University Of Massachusetts | Aav capsids variants and uses thereof |
WO2021202651A1 (en) | 2020-04-01 | 2021-10-07 | Voyager Therapeutics, Inc. | Redirection of tropism of aav capsids |
WO2021207592A1 (en) | 2020-04-09 | 2021-10-14 | 4Mvac Llc | Use of viral vectors for coronavirus vaccine production |
WO2021211753A1 (en) | 2020-04-15 | 2021-10-21 | Voyager Therapeutics, Inc. | Tau binding compounds |
WO2021214443A1 (en) | 2020-04-20 | 2021-10-28 | Synpromics Limited | Regulatory nucleic acid sequences |
US11166996B2 (en) | 2018-12-12 | 2021-11-09 | Flagship Pioneering Innovations V, Inc. | Anellovirus compositions and methods of use |
WO2021231567A2 (en) | 2020-05-13 | 2021-11-18 | Akouos, Inc. | Compositions and methods for treating slc26a4-associated hearing loss |
WO2021230987A1 (en) | 2020-05-13 | 2021-11-18 | Voyager Therapeutics, Inc. | Redirection of tropism of aav capsids |
WO2021231538A2 (en) | 2020-05-13 | 2021-11-18 | Akouos, Inc. | Compositions and methods for treating kcnq4-associated hearing loss |
WO2021247995A2 (en) | 2020-06-04 | 2021-12-09 | Voyager Therapeutics, Inc. | Compositions and methods of treating neuropathic pain |
WO2022013221A1 (en) | 2020-07-13 | 2022-01-20 | Transgene | Treatment of immune depression |
WO2022032153A1 (en) | 2020-08-06 | 2022-02-10 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
WO2022032140A2 (en) | 2020-08-07 | 2022-02-10 | Amicus Therapeutics, Inc. | Vesicle targeting proteins and uses of same |
EP3957331A1 (en) | 2016-03-03 | 2022-02-23 | University Of Massachusetts | Closed-ended linear duplex dna for non-viral gene transfer |
WO2022051555A2 (en) | 2020-09-03 | 2022-03-10 | Rampart Bioscience, Inc. | Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs |
WO2022049385A1 (en) | 2020-09-04 | 2022-03-10 | Asklepios Biopharmaceutical, Inc. | Regulatory nucleic acid sequences |
US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
WO2022094461A1 (en) | 2020-11-02 | 2022-05-05 | Biomarin Pharmaceutical Inc. | Process for enriching adeno-associated virus |
US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
WO2022119839A1 (en) | 2020-12-01 | 2022-06-09 | Akouos, Inc. | Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms |
WO2022140560A1 (en) | 2020-12-23 | 2022-06-30 | Flagship Pioneering Innovations V, Inc. | In vitro assembly of anellovirus capsids enclosing rna |
WO2022146839A1 (en) | 2020-12-29 | 2022-07-07 | Akouos, Inc. | Compositions and methods for treating clrn1-associated hearing loss and/or vision loss |
WO2022147480A1 (en) | 2020-12-30 | 2022-07-07 | Ansun Biopharma, Inc. | Oncolytic virus encoding sialidase and multispecific immune cell engager |
EP4039813A1 (en) | 2013-07-12 | 2022-08-10 | The Children's Hospital of Philadelphia | Aav vector and assay for anti-aav (adeno-associated virus) neutralizing antibodies |
WO2022187473A2 (en) | 2021-03-03 | 2022-09-09 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
WO2022187548A1 (en) | 2021-03-03 | 2022-09-09 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
WO2022214632A1 (en) | 2021-04-07 | 2022-10-13 | Neoplants Sas | Compositions and methods for indoor air remediation |
US11479516B2 (en) | 2015-10-05 | 2022-10-25 | Massachusetts Institute Of Technology | Nitrogen fixation using refactored NIF clusters |
WO2022235586A1 (en) | 2021-05-03 | 2022-11-10 | Astellas Institute For Regenerative Medicine | Methods of generating mature corneal endothelial cells |
US11497576B2 (en) | 2017-07-17 | 2022-11-15 | Voyager Therapeutics, Inc. | Trajectory array guide system |
US11525139B2 (en) | 2016-08-23 | 2022-12-13 | Akouos, Inc. | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
US11565979B2 (en) | 2017-01-12 | 2023-01-31 | Pivot Bio, Inc. | Methods and compositions for improving plant traits |
WO2023019203A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Inducible systems for altering gene expression in hypoimmunogenic cells |
WO2023034990A1 (en) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
WO2023034996A1 (en) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
WO2023034980A1 (en) | 2021-09-03 | 2023-03-09 | Bomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
WO2023034997A1 (en) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
WO2023034994A1 (en) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
WO2023034989A1 (en) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
US11603542B2 (en) | 2017-05-05 | 2023-03-14 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
WO2023044483A2 (en) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
WO2023056329A1 (en) | 2021-09-30 | 2023-04-06 | Akouos, Inc. | Compositions and methods for treating kcnq4-associated hearing loss |
EP4169576A1 (en) | 2018-03-23 | 2023-04-26 | University of Massachusetts | Gene therapeutics for treating bone disorders |
WO2023081648A1 (en) | 2021-11-02 | 2023-05-11 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
WO2023091948A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
WO2023107188A1 (en) | 2021-12-10 | 2023-06-15 | Massachusetts Institute Of Technology | Prediction, biosynthesis, and integration as biosensors of molecules with unique light absorbance signatures and their subsequent in-field remote detection using multi or hyper-spectral cameras |
WO2023111580A1 (en) | 2021-12-16 | 2023-06-22 | University Of Dundee | Targeted degradation of alpha-synuclein |
US11697801B2 (en) | 2017-12-19 | 2023-07-11 | Akouos, Inc. | AAV-mediated delivery of therapeutic antibodies to the inner ear |
US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
WO2023147374A2 (en) | 2022-01-25 | 2023-08-03 | Voyager Therapeutics, Inc. | Baculovirus expression system |
WO2023150142A1 (en) | 2022-02-02 | 2023-08-10 | Akouos, Inc. | Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms |
WO2023152504A1 (en) | 2022-02-10 | 2023-08-17 | University Of Dundee | An affinity-directed phosphatase system for targeted protein dephosphorylation |
WO2023154693A1 (en) | 2022-02-08 | 2023-08-17 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
US11739346B2 (en) | 2017-04-05 | 2023-08-29 | University Of Massachusetts | Minigene therapy |
US11739345B2 (en) | 2018-05-09 | 2023-08-29 | Biomarin Pharmaceutical Inc. | Methods of treating phenylketonuria |
US11752181B2 (en) | 2017-05-05 | 2023-09-12 | Voyager Therapeutics, Inc. | Compositions and methods of treating Huntington's disease |
US11759506B2 (en) | 2017-06-15 | 2023-09-19 | Voyager Therapeutics, Inc. | AADC polynucleotides for the treatment of Parkinson's disease |
US11773407B2 (en) | 2017-06-26 | 2023-10-03 | Arizona Board Of Regents On Behalf Of Arizona State University | CRISPR logic circuits for safer and controllable gene therapies |
WO2023196862A1 (en) | 2022-04-06 | 2023-10-12 | Genzyme Corporation | Targeted gene therapy for dm-1 myotonic dystrophy |
WO2023201273A1 (en) | 2022-04-12 | 2023-10-19 | Genzyme Corporation | Dendritic cell assay for innate immunogenicity to gene therapy agents |
WO2023200843A1 (en) | 2022-04-12 | 2023-10-19 | The Broad Institute, Inc. | Compositions and methods for screening cis regulatory elements |
WO2023201272A1 (en) | 2022-04-12 | 2023-10-19 | Genzyme Corporation | Use of irak4 modulators for gene therapy |
WO2023201274A1 (en) | 2022-04-12 | 2023-10-19 | Genzyme Corporation | Use of an irak4 modulator for gene therapy |
WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
WO2023220729A2 (en) | 2022-05-13 | 2023-11-16 | Flagship Pioneering Innovations Vii, Llc | Double stranded dna compositions and related methods |
WO2023235791A1 (en) | 2022-06-02 | 2023-12-07 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
WO2024003353A1 (en) | 2022-07-01 | 2024-01-04 | Transgene | Fusion protein comprising a surfactant-protein-d and a member of the tnfsf |
WO2024006741A1 (en) | 2022-06-28 | 2024-01-04 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
WO2024009280A1 (en) | 2022-07-08 | 2024-01-11 | Baylor College Of Medicine | Integrated stress response inhibitors and methods of using the same |
WO2024011112A1 (en) | 2022-07-06 | 2024-01-11 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
US11884925B2 (en) | 2018-11-08 | 2024-01-30 | Arizona Board Of Regents On Behalf Of Arizona State University | Synthetic immunomodulation with a CRISPR super-repressor in vivo |
US11890329B2 (en) | 2017-07-06 | 2024-02-06 | The Trustees Of The University Of Pennsylvania | AAV9-mediated gene therapy for treating mucopolysaccharidosis type I |
WO2024054983A1 (en) | 2022-09-08 | 2024-03-14 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
WO2024059739A1 (en) | 2022-09-15 | 2024-03-21 | Voyager Therapeutics, Inc. | Tau binding compounds |
WO2024064856A1 (en) | 2022-09-22 | 2024-03-28 | Biomarin Pharmaceutical Inc. | Treatment of cardiomyopathy with aav gene therapy vectors |
WO2024064863A2 (en) | 2022-09-22 | 2024-03-28 | Biomarin Pharmaceutical Inc. | Treatment of arrhythmogenic cardiomyopathy with aav gene therapy vectors |
US11946162B2 (en) | 2012-11-01 | 2024-04-02 | Massachusetts Institute Of Technology | Directed evolution of synthetic gene cluster |
EP4345106A1 (en) | 2022-09-30 | 2024-04-03 | Charité - Universitätsmedizin Berlin | Gene therapy vectors for the expression of preprodynorphin variants for the treatment of epilepsy |
WO2024069010A1 (en) | 2022-09-30 | 2024-04-04 | Charité - Universitätsmedizin Berlin | Gene therapy vectors for the expression of preprodynorphin variants for the treatment of epilepsy |
US11951121B2 (en) | 2016-05-18 | 2024-04-09 | Voyager Therapeutics, Inc. | Compositions and methods for treating Huntington's disease |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3807404A1 (en) | 2018-06-13 | 2021-04-21 | Voyager Therapeutics, Inc. | Engineered 5' untranslated regions (5' utr) for aav production |
CA3115248A1 (en) | 2018-10-05 | 2020-04-09 | Voyager Therapeutics, Inc. | Engineered nucleic acid constructs encoding aav production proteins |
JP2022505106A (en) | 2018-10-15 | 2022-01-14 | ボイジャー セラピューティクス インコーポレイテッド | Expression vector for large-scale production of rAAV in the baculovirus / Sf9 system |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991000905A1 (en) * | 1989-07-07 | 1991-01-24 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | Rapid, versatile and simple system for expressing genes in eukaryotic cells |
WO1994013788A1 (en) * | 1992-12-04 | 1994-06-23 | University Of Pittsburgh | Recombinant viral vector system |
WO1994026911A1 (en) * | 1993-05-14 | 1994-11-24 | Ohio University Edison Animal Biotechnology Institute | A gene expression system utilizing an rna polymerase prebound to dna |
WO1995013365A1 (en) * | 1993-11-09 | 1995-05-18 | Targeted Genetics Corporation | Generation of high titers of recombinant aav vectors |
WO1995013392A1 (en) * | 1993-11-09 | 1995-05-18 | Medical College Of Ohio | Stable cell lines capable of expressing the adeno-associated virus replication gene |
WO1995014771A1 (en) * | 1993-11-24 | 1995-06-01 | GOVERNMENT OF THE UNITED STATES, represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES: National Institutes of Health | Vector systems for the generation of adeno-associated virus particles |
WO1996012010A1 (en) * | 1994-10-13 | 1996-04-25 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Preparation of rep-negative aav mutants and cells which can be used therefor |
WO1996013598A2 (en) * | 1994-10-28 | 1996-05-09 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-aav virus and method of use thereof |
WO1996014061A1 (en) * | 1994-11-03 | 1996-05-17 | Cell Genesys, Inc. | Novel adenoviral vectors, packaging cell lines, recombinant adenoviruses and methods |
WO1996017947A1 (en) * | 1994-12-06 | 1996-06-13 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant aav vectors |
WO1997000947A1 (en) * | 1995-06-23 | 1997-01-09 | Rhone-Poulenc Rorer S.A. | Recombinant adenoviruses, use thereof for preparing aavs, complementary cell line, and pharmaceutical compositions containing said adenoviruses |
-
1997
- 1997-09-04 JP JP10512963A patent/JP2001500015A/en active Pending
- 1997-09-04 WO PCT/US1997/015716 patent/WO1998010088A1/en not_active Application Discontinuation
- 1997-09-04 EP EP97939829A patent/EP0931158A1/en not_active Withdrawn
- 1997-09-04 CA CA002264482A patent/CA2264482A1/en not_active Abandoned
- 1997-09-04 IL IL12878097A patent/IL128780A0/en unknown
- 1997-09-04 AU AU41833/97A patent/AU722624B2/en not_active Ceased
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991000905A1 (en) * | 1989-07-07 | 1991-01-24 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | Rapid, versatile and simple system for expressing genes in eukaryotic cells |
WO1994013788A1 (en) * | 1992-12-04 | 1994-06-23 | University Of Pittsburgh | Recombinant viral vector system |
WO1994026911A1 (en) * | 1993-05-14 | 1994-11-24 | Ohio University Edison Animal Biotechnology Institute | A gene expression system utilizing an rna polymerase prebound to dna |
WO1995013365A1 (en) * | 1993-11-09 | 1995-05-18 | Targeted Genetics Corporation | Generation of high titers of recombinant aav vectors |
WO1995013392A1 (en) * | 1993-11-09 | 1995-05-18 | Medical College Of Ohio | Stable cell lines capable of expressing the adeno-associated virus replication gene |
WO1995014771A1 (en) * | 1993-11-24 | 1995-06-01 | GOVERNMENT OF THE UNITED STATES, represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES: National Institutes of Health | Vector systems for the generation of adeno-associated virus particles |
WO1996012010A1 (en) * | 1994-10-13 | 1996-04-25 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Preparation of rep-negative aav mutants and cells which can be used therefor |
WO1996013598A2 (en) * | 1994-10-28 | 1996-05-09 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-aav virus and method of use thereof |
WO1996014061A1 (en) * | 1994-11-03 | 1996-05-17 | Cell Genesys, Inc. | Novel adenoviral vectors, packaging cell lines, recombinant adenoviruses and methods |
WO1996017947A1 (en) * | 1994-12-06 | 1996-06-13 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant aav vectors |
WO1997000947A1 (en) * | 1995-06-23 | 1997-01-09 | Rhone-Poulenc Rorer S.A. | Recombinant adenoviruses, use thereof for preparing aavs, complementary cell line, and pharmaceutical compositions containing said adenoviruses |
Non-Patent Citations (6)
Title |
---|
A. LIEBER ET AL.: "High level gene expression in mammalian cells by a nuclear T7-phage RNA polymerase", NUCLEIC ACIDS RESEARCH, vol. 17, no. 21, - 1989, IRL PRESS LIMITED,OXFORD,ENGLAND, pages 8485 - 8493, XP002052543 * |
CLARK K R ET AL: "CELL LINES FOR THE PRODUCTION OF RECOMBINANT ADENO-ASSOCIATED VIRUS", HUMAN GENE THERAPY, vol. 6, no. 10, 1 October 1995 (1995-10-01), pages 1329 - 1341, XP000569718 * |
ELROY-STEIN O ET AL: "CYTOPLASMIC EXPRESSION SYSTEM BASED ON CONSTITUTIVE SYNTHESIS OF BACTERIOPHAGE T7 POLYMERASE IN MAMMALIAN CELLS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 87, no. 17, 1 September 1990 (1990-09-01), pages 6743 - 6747, XP000563742 * |
FUERST T R ET AL: "EUKARYOTIC TRANSIENT-EXPRESSION SYSTEM BASED ON RECOMBINANT VACCINIA VIRUS THAT SYNTHESIZES BACTERIOPHAGE T7 RNA POLYMERASE", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 83, no. 21, 1 November 1986 (1986-11-01), pages 8122 - 8126, XP000563743 * |
KOTIN R M: "PROSPECTS FOR THE USE OF ADENO-ASSOCIATED VIRUS AS A VECTOR FOR HUMAN GENE THERAPY", HUMAN GENE THERAPY, vol. 5, 1994, pages 793 - 801, XP000651491 * |
LEONARD, C. J. ET AL: "Cloning, expression, and partial purification of Rep78: an adeno - associated virus replication protein", VIROLOGY (1994), 200(2), 566-73 CODEN: VIRLAX;ISSN: 0042-6822, 1994, XP002052542 * |
Cited By (325)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6924128B2 (en) | 1994-12-06 | 2005-08-02 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant AAV vectors |
US6995006B2 (en) | 1997-09-05 | 2006-02-07 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US6989264B2 (en) | 1997-09-05 | 2006-01-24 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US6953690B1 (en) | 1998-03-20 | 2005-10-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
US6451594B1 (en) | 1998-09-11 | 2002-09-17 | The Regents Of The University Of California | Recombinant adenovirus for tissue specific expression in heart |
WO2000015821A1 (en) * | 1998-09-11 | 2000-03-23 | The Regents Of The University Of California | Recombinant adenovirus for tissue specific expression in heart |
US8637255B2 (en) | 1998-11-05 | 2014-01-28 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype I nucleic acid sequences, vectors and host cells containing same |
US6759237B1 (en) | 1998-11-05 | 2004-07-06 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
US9163260B2 (en) | 1998-11-05 | 2015-10-20 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype I nucleic acid sequences, vectors and host cells containing same |
US7105345B2 (en) | 1998-11-05 | 2006-09-12 | The University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
US7186552B2 (en) | 1998-11-05 | 2007-03-06 | The Trustees Of University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
US9567607B2 (en) | 1998-11-05 | 2017-02-14 | Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype I nucleic acid sequences, vectors and host cells containing same |
US6485966B2 (en) | 1999-03-18 | 2002-11-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
US7022519B2 (en) | 1999-03-18 | 2006-04-04 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
US6893865B1 (en) | 1999-04-28 | 2005-05-17 | Targeted Genetics Corporation | Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles |
US6793926B1 (en) | 1999-05-27 | 2004-09-21 | Genovo, Inc. | Methods for production of a recombinant adeno-associated virus |
US7115391B1 (en) | 1999-10-01 | 2006-10-03 | Genovo, Inc. | Production of recombinant AAV using adenovirus comprising AAV rep/cap genes |
US11034976B2 (en) | 2001-11-13 | 2021-06-15 | The Trustees Of The University Of Pennsylvania | Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby |
US10508286B2 (en) | 2001-11-13 | 2019-12-17 | The Trustees Of The University Of Pennsylvania | Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby |
US8524446B2 (en) | 2001-11-13 | 2013-09-03 | The Trustees Of The University Of Pennsylvania | Method for detecting adeno-associated virus |
US8906675B2 (en) | 2001-11-13 | 2014-12-09 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby |
US11499167B2 (en) | 2001-11-13 | 2022-11-15 | The Trustees Of The University Of Pennsylvania | Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby |
US10544432B2 (en) | 2001-11-13 | 2020-01-28 | The Trustees Of The University Of Pennsylvania | Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby |
US10526617B2 (en) | 2001-11-13 | 2020-01-07 | The Trustees Of The University Of Pennsylvania | Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby |
US11041171B2 (en) | 2001-11-13 | 2021-06-22 | The Trustees Of The University Of Pennsylvania | Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby |
US10308958B2 (en) | 2001-11-13 | 2019-06-04 | The Trustees Of The University Of Pennsylvania | Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby |
US11377669B2 (en) | 2001-11-13 | 2022-07-05 | The Trustees Of The University Of Pennsylvania | Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby |
US10041090B2 (en) | 2001-11-13 | 2018-08-07 | The Trustees Of The University Of Pennsylvania | Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby |
US9790472B2 (en) | 2001-11-13 | 2017-10-17 | The Trustees Of The University Of Pennsylvania | Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby |
US11034977B2 (en) | 2001-11-13 | 2021-06-15 | The Trustees Of The University Of Pennsylvania | Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby |
EP2341068A1 (en) | 2001-11-13 | 2011-07-06 | The Trustees of The University of Pennsylvania | A method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby |
EP2338900A1 (en) | 2001-11-13 | 2011-06-29 | The Trustees of The University of Pennsylvania | A method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby |
EP2286841A1 (en) | 2001-11-21 | 2011-02-23 | The Trustees of The University of Pennsylvania | Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
EP3108899A1 (en) | 2001-11-21 | 2016-12-28 | The Trustees of the University of Pennsylvania | Simian adenovirus adsv1 nucleic acid and amino acid sequences, vectors containing same, and methods of use |
EP2301582A1 (en) | 2001-11-21 | 2011-03-30 | The Trustees of The University of Pennsylvania | Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
EP1944043A1 (en) | 2001-11-21 | 2008-07-16 | The Trustees of the University of Pennsylvania | Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
WO2003046124A2 (en) | 2001-11-21 | 2003-06-05 | The Trustees Of The University Of Pennsylvania | Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
EP2573170A2 (en) | 2001-12-17 | 2013-03-27 | The Trustees of the University of Pennsylvania | Adeno-associated virus (AAV) serotype 9 sequences, vectors containing same, and uses therefor |
US9677089B2 (en) | 2001-12-17 | 2017-06-13 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
EP2359869A2 (en) | 2001-12-17 | 2011-08-24 | The Trustees of The University of Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same and uses therefor |
EP3517134A1 (en) | 2001-12-17 | 2019-07-31 | The Trustees of the University of Pennsylvania | Adeno-associated virus (aav) serotype 8 sequences, vectors containing same and uses therefor |
US10301650B2 (en) | 2001-12-17 | 2019-05-28 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
US10266846B2 (en) | 2001-12-17 | 2019-04-23 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
US10590435B2 (en) | 2001-12-17 | 2020-03-17 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
US11396663B2 (en) | 2001-12-17 | 2022-07-26 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
US11390883B2 (en) | 2001-12-17 | 2022-07-19 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
US8962332B2 (en) | 2001-12-17 | 2015-02-24 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
US7790449B2 (en) | 2001-12-17 | 2010-09-07 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors containing the same, and uses therefor |
US9587250B2 (en) | 2001-12-17 | 2017-03-07 | Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
US7282199B2 (en) | 2001-12-17 | 2007-10-16 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
US7198951B2 (en) | 2001-12-17 | 2007-04-03 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 9 sequences, vectors containing same, and uses therefor |
US8318480B2 (en) | 2001-12-17 | 2012-11-27 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
US9493788B2 (en) | 2001-12-17 | 2016-11-15 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
US8962330B2 (en) | 2001-12-17 | 2015-02-24 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
WO2003078453A1 (en) | 2002-03-15 | 2003-09-25 | Wyeth Holdings Corporation | Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity |
EP1925626A1 (en) | 2003-07-21 | 2008-05-28 | Transgene S.A. | Novel multifunctional cytokines |
EP1944318A1 (en) | 2003-07-21 | 2008-07-16 | Transgene S.A. | Novel multifunctional cytokines |
US8986282B2 (en) | 2003-09-26 | 2015-03-24 | The Trustees Of The University Of Pennsylvania | Methods, compositions and apparatus for delivering heterologous molecules to cells |
US8303567B2 (en) | 2003-09-26 | 2012-11-06 | The Trustees Of The University Of Pennsylvania | Method for delivering a macromolecular complex to muscle cells |
US9283357B2 (en) | 2003-09-26 | 2016-03-15 | The Trustees Of The University Of Pennsylvania | Methods, compositions and apparatus for delivering heterologous molecules to cells |
EP2292779A2 (en) | 2003-09-30 | 2011-03-09 | The Trustees of the University of Pennsylvania | Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof |
EP2298926A1 (en) | 2003-09-30 | 2011-03-23 | The Trustees of The University of Pennsylvania | Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof |
EP2345731A1 (en) | 2003-09-30 | 2011-07-20 | The Trustees of the University of Pennsylvania | Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof |
EP2292780A2 (en) | 2003-09-30 | 2011-03-09 | The Trustees of the University of Pennsylvania | Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof |
EP2116605A2 (en) | 2004-06-17 | 2009-11-11 | Wyeth | Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV |
US8556842B2 (en) | 2004-09-30 | 2013-10-15 | The Trustees Of The University Of Pennsylvania | Perfusion circuit and use therein in targeted delivery of macromolecules |
EP2123306A1 (en) | 2004-12-03 | 2009-11-25 | Fondazione Telethon | Use of a decoy protein that interferes with the hedgehog signalling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization |
EP4282957A2 (en) | 2005-04-07 | 2023-11-29 | The Trustees of the University of Pennsylvania | Method of increasing the function of an aav vector |
EP2359866A1 (en) | 2005-04-07 | 2011-08-24 | The Trustees of The University of Pennsylvania | Method of increasing the function of an AAV vector |
EP2359865A1 (en) | 2005-04-07 | 2011-08-24 | The Trustees of The University of Pennsylvania | Method of increasing the function of an AAV vector |
EP2359867A1 (en) | 2005-04-07 | 2011-08-24 | The Trustees of The University of Pennsylvania | Method of increasing the function of an AAV vector |
EP2357010A1 (en) | 2005-04-07 | 2011-08-17 | The Trustees of The University of Pennsylvania | Method of increasing the function of an AAV vector |
EP3603676A1 (en) | 2005-04-07 | 2020-02-05 | The Trustees of the University of Pennsylvania | Method of increasing the function of an aav vector |
EP3085389A1 (en) | 2005-04-07 | 2016-10-26 | The Trustees Of The University Of Pennsylvania | Method of increasing the function of an aav vector |
EP4282956A2 (en) | 2005-04-07 | 2023-11-29 | The Trustees of the University of Pennsylvania | Method of increasing the function of an aav vector |
EP2383346A1 (en) | 2005-04-07 | 2011-11-02 | The Trustees of the University of Pennsylvania | Method of increasing the function of an AAV vector |
US8632995B2 (en) | 2006-07-27 | 2014-01-21 | Wyeth Llc | High-cell density fed-batch fermentation process for producing recombinant protein |
US9279000B2 (en) | 2006-07-27 | 2016-03-08 | Wyeth Llc | High-cell density fed-batch fermentation process for producing recombinant protein |
EP3705579A1 (en) | 2006-07-27 | 2020-09-09 | Wyeth LLC | High-cell density fed-batch fermentation process for producing recombinant protein |
US10301663B2 (en) | 2006-07-27 | 2019-05-28 | Wyeth, Llc | High-cell density fed-batch fermentation process for producing recombinant protein |
EP3128010A1 (en) | 2007-11-28 | 2017-02-08 | The Trustees Of The University Of Pennsylvania | Simian subfamily e adenoviruses sadv-30 and uses thereof |
EP2463362A1 (en) | 2007-11-28 | 2012-06-13 | The Trustees of The University of Pennsylvania | Simian subfamily c adenovirus SAdv-31 and uses thereof |
EP2325298A2 (en) | 2008-03-04 | 2011-05-25 | The Trustees of The University of Pennsylvania | Simian adenoviruses SAdV-36, -42.1, -42.2, AND -44 and uses thereof |
EP2774985A1 (en) | 2008-10-31 | 2014-09-10 | The Trustees of The University of Pennsylvania | Simian adenovirus SAdV-43 and uses thereof |
WO2010051367A1 (en) | 2008-10-31 | 2010-05-06 | The Trustees Of The University Of Pennsylvania | Simian adenoviruses sadv-43, -45,-48,-49, and -50 and uses thereof |
US10920244B2 (en) | 2009-04-30 | 2021-02-16 | The Trustees Of The University Of Pennsylvania | Compositions for targeting conducting airway cells comprising adeno-associated virus constructs |
WO2010138675A1 (en) | 2009-05-29 | 2010-12-02 | The Trustees Of The University Of Pennsylvania | Simian adenovirus 41 and uses thereof |
WO2011053998A3 (en) * | 2009-11-02 | 2011-11-24 | The Salk Institute For Biological Studies | Targeting of modifying enzymes for protein evolution |
WO2011053998A2 (en) * | 2009-11-02 | 2011-05-05 | The Salk Institute For Biological Studies | Targeting of modifying enzymes for protein evolution |
EP2826860A1 (en) | 2010-04-23 | 2015-01-21 | The University of Massachusetts | CNS targeting AAV vectors and methods of use thereof |
EP3536781A1 (en) | 2010-04-23 | 2019-09-11 | University of Massachusetts | Cns targeting aav vectors and methods of use thereof |
EP3540055A1 (en) | 2010-04-23 | 2019-09-18 | University of Massachusetts | Cns targeting aav vectors and methods of use thereof |
EP3567106A1 (en) | 2010-04-23 | 2019-11-13 | University of Massachusetts | Cns targeting aav vectors and methods of use thereof |
EP3514232A1 (en) | 2010-04-23 | 2019-07-24 | University of Massachusetts | Cns targeting aav vectors and methods of use thereof |
WO2011133890A1 (en) | 2010-04-23 | 2011-10-27 | University Of Massachusetts | Cns targeting aav vectors and methods of use thereof |
WO2012040550A1 (en) | 2010-09-26 | 2012-03-29 | Da Yu Enterprises, L.L.C. | Method of recombinant macromolecular production |
WO2012071318A2 (en) | 2010-11-23 | 2012-05-31 | The Trustees Of The University Of Pennsylvania | Subfamily e simian adenoviruses a1321, a1325, a1295, a1309, a1316 and a1322 and uses thereof |
WO2012076715A1 (en) | 2010-12-09 | 2012-06-14 | Institut Pasteur | Mgmt-based method for obtaining high yield of recombinant protein expression |
EP3202897A1 (en) | 2010-12-09 | 2017-08-09 | Institut Pasteur | Mgmt-based method for obtaining high yield of recombinant protein expression |
US11766448B2 (en) | 2011-02-17 | 2023-09-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for altering tissue specificity and improving AAV9-mediated gene transfer |
US9884071B2 (en) | 2011-02-17 | 2018-02-06 | The Trustees Of The University Of Pennsylvania | Compositions and methods for altering tissue specificity and improving AAV9-mediated gene transfer |
WO2012112832A1 (en) | 2011-02-17 | 2012-08-23 | The Trustees Of The University Of Pennsylvania | Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer |
US10406173B2 (en) | 2011-02-17 | 2019-09-10 | Trustees Of The University Of Pennsylvania | Compositions and methods for altering tissue specificity and improving AAV9-mediated gene transfer |
US10918658B2 (en) | 2011-02-17 | 2021-02-16 | The Trustees Of The University Of Pennsylvania | Compositions and methods for altering tissue specificity and improving AAV9-mediated gene transfer |
WO2012156535A1 (en) | 2011-05-19 | 2012-11-22 | Fundación Progreso Y Salud | Highly inducible dual-promoter lentiviral tet-on system |
WO2013043720A1 (en) | 2011-09-20 | 2013-03-28 | The University Of North Carolina At Chapel Hill | Regulation of sodium channels by plunc proteins |
EP3539568A1 (en) | 2011-11-22 | 2019-09-18 | The Children's Hospital of Philadelphia | Virus vectors for highly efficient transgene delivery |
WO2013083847A2 (en) | 2011-12-09 | 2013-06-13 | Institut Pasteur | Multiplex immuno screening assay |
WO2013158879A1 (en) | 2012-04-18 | 2013-10-24 | The Children's Hospital Of Philadelphia | Composition and methods for highly efficient gene transfer using aav capsid variants |
WO2013173702A2 (en) | 2012-05-18 | 2013-11-21 | The Trustees Of The University Of Pennsylvania | Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof |
EP3587455A1 (en) | 2012-10-23 | 2020-01-01 | Emory University | Gm-csf and il-4 conjugates, compositions, and methods related thereto |
WO2014066443A1 (en) | 2012-10-23 | 2014-05-01 | Emory University | Gm-csf and il-4 conjugates, compositions, and methods related thereto |
WO2014068072A1 (en) | 2012-10-31 | 2014-05-08 | Institut Gustave-Roussy | Identification, assessment and therapy of essential thrombocythemia with resistance to jak2 inhibitors |
US11946162B2 (en) | 2012-11-01 | 2024-04-02 | Massachusetts Institute Of Technology | Directed evolution of synthetic gene cluster |
US9523084B2 (en) | 2012-11-08 | 2016-12-20 | Centre National De La Recherche Scientifique (Cnrs) | Phosphodeoxyribosyl transferase mutant enzymes and uses thereof |
US10792343B2 (en) | 2013-03-15 | 2020-10-06 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating MPSI |
US10137176B2 (en) | 2013-03-15 | 2018-11-27 | The Trustee Of The University Of Pennsylvania | Compositions and methods for treating MPSI |
EP3747998A1 (en) | 2013-03-15 | 2020-12-09 | The Trustees of the University of Pennsylvania | Compositions for treating mpsi |
EP4039813A1 (en) | 2013-07-12 | 2022-08-10 | The Children's Hospital of Philadelphia | Aav vector and assay for anti-aav (adeno-associated virus) neutralizing antibodies |
EP3613440A1 (en) | 2013-07-22 | 2020-02-26 | The Children's Hospital of Philadelphia | Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues |
US11732246B2 (en) | 2014-03-09 | 2023-08-22 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency |
US9890365B2 (en) | 2014-03-09 | 2018-02-13 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency |
US10167454B2 (en) | 2014-03-09 | 2019-01-01 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency |
US10626382B2 (en) | 2014-03-09 | 2020-04-21 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency |
US10781430B2 (en) | 2014-03-09 | 2020-09-22 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency |
WO2015164786A1 (en) | 2014-04-25 | 2015-10-29 | University Of Massachusetts | Recombinant aav vectors useful for reducing immunity against transgene products |
US10982228B2 (en) | 2014-05-02 | 2021-04-20 | Genzyme Corporation | AAV vectors for retinal and CNS gene therapy |
EP3913061A1 (en) | 2014-05-02 | 2021-11-24 | Genzyme Corporation | Aav vectors for retinal and cns gene therapy |
WO2015168666A2 (en) | 2014-05-02 | 2015-11-05 | Genzyme Corporation | Aav vectors for retinal and cns gene therapy |
US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
EP3552615A1 (en) | 2014-07-16 | 2019-10-16 | Transgene SA | Oncolytic virus for expression of immune checkpoint modulators |
WO2016054557A1 (en) | 2014-10-03 | 2016-04-07 | University Of Massachusetts | Novel high efficiency library-identified aav vectors |
EP3795580A1 (en) | 2014-10-03 | 2021-03-24 | University of Massachusetts | High efficiency library-identified aav vectors |
WO2016065001A1 (en) | 2014-10-21 | 2016-04-28 | University Of Massachusetts | Recombinant aav variants and uses thereof |
US11027000B2 (en) | 2014-11-05 | 2021-06-08 | Voyager Therapeutics, Inc. | AADC polynucleotides for the treatment of Parkinson's disease |
US10335466B2 (en) | 2014-11-05 | 2019-07-02 | Voyager Therapeutics, Inc. | AADC polynucleotides for the treatment of parkinson's disease |
US10920227B2 (en) | 2014-11-14 | 2021-02-16 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
US10597660B2 (en) | 2014-11-14 | 2020-03-24 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
US11198873B2 (en) | 2014-11-14 | 2021-12-14 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
US10570395B2 (en) | 2014-11-14 | 2020-02-25 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
US11542506B2 (en) | 2014-11-14 | 2023-01-03 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
WO2016122791A1 (en) | 2015-01-30 | 2016-08-04 | The Regents Of The University Of California | Spinal subpial gene delivery system |
US10760079B2 (en) | 2015-02-10 | 2020-09-01 | Genzyme Corporation | Variant RNAi |
US10450563B2 (en) | 2015-02-10 | 2019-10-22 | Genzyme Corporation | Variant RNAi |
WO2016130591A2 (en) | 2015-02-10 | 2016-08-18 | Genzyme Corporation | Enhanced delivery of viral particles to the striatum and cortex |
US11781137B2 (en) | 2015-02-10 | 2023-10-10 | Genzyme Corporation | Variant RNAi |
WO2016130589A2 (en) | 2015-02-10 | 2016-08-18 | Genzyme Corporation | VARIANT RNAi |
EP4023758A1 (en) | 2015-02-10 | 2022-07-06 | Genzyme Corporation | Enhanced delivery of viral particles to the striatum and cortex |
EP4219728A2 (en) | 2015-02-10 | 2023-08-02 | Genzyme Corporation | Enhanced delivery of viral particles to the striatum and cortex |
WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
WO2016145217A1 (en) | 2015-03-10 | 2016-09-15 | The Trustees Of Columbia University In The City Of New York | Recombinant glut1 adeno-associated viral vector constructs and related methods for restoring glut1 expression |
WO2016164609A2 (en) | 2015-04-08 | 2016-10-13 | Genzyme Corporation | Production of oversized adeno-associated vectors |
WO2016172155A1 (en) | 2015-04-23 | 2016-10-27 | University Of Massachusetts | Modulation of aav vector transgene expression |
WO2016186772A2 (en) | 2015-05-16 | 2016-11-24 | Genzyme Corporation | Gene editing of deep intronic mutations |
WO2016210170A1 (en) | 2015-06-23 | 2016-12-29 | The Children's Hospital Of Philadelphia | Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues |
US11739032B2 (en) | 2015-07-13 | 2023-08-29 | Pivot Bio, Inc. | Methods and compositions for improving plant traits |
US10919814B2 (en) | 2015-07-13 | 2021-02-16 | Pivot Bio, Inc. | Methods and compositions for improving plant traits |
US10934226B2 (en) | 2015-07-13 | 2021-03-02 | Pivot Bio, Inc. | Methods and compositions for improving plant traits |
US11479516B2 (en) | 2015-10-05 | 2022-10-25 | Massachusetts Institute Of Technology | Nitrogen fixation using refactored NIF clusters |
WO2017070525A1 (en) | 2015-10-22 | 2017-04-27 | University Of Massachusetts | Methods and compositions for treating metabolic imbalance in neurodegenerative disease |
WO2017075335A1 (en) | 2015-10-28 | 2017-05-04 | Voyager Therapeutics, Inc. | Regulatable expression using adeno-associated virus (aav) |
WO2017096164A1 (en) | 2015-12-02 | 2017-06-08 | The Board Of Trustees Of The Leland Stanford Junior University | Novel recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism |
US10973929B2 (en) | 2016-02-03 | 2021-04-13 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type I |
EP4094780A2 (en) | 2016-02-12 | 2022-11-30 | University of Massachusetts | Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization |
WO2017139643A1 (en) | 2016-02-12 | 2017-08-17 | University Of Massachusetts | Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization |
WO2017143100A1 (en) | 2016-02-16 | 2017-08-24 | The Board Of Trustees Of The Leland Stanford Junior University | Novel recombinant adeno-associated virus capsids resistant to pre-existing human neutralizing antibodies |
WO2017147128A1 (en) | 2016-02-22 | 2017-08-31 | The University Of North Carolina At Chapel Hill | Peptide inhibitors of calcium channels |
EP3957331A1 (en) | 2016-03-03 | 2022-02-23 | University Of Massachusetts | Closed-ended linear duplex dna for non-viral gene transfer |
US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
WO2017191147A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
WO2017194912A1 (en) | 2016-05-09 | 2017-11-16 | Cambridge Enterprise Limited | Treatment of complement-mediated disorders |
US10584337B2 (en) | 2016-05-18 | 2020-03-10 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
US11951121B2 (en) | 2016-05-18 | 2024-04-09 | Voyager Therapeutics, Inc. | Compositions and methods for treating Huntington's disease |
US11193129B2 (en) | 2016-05-18 | 2021-12-07 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
WO2017216301A1 (en) | 2016-06-16 | 2017-12-21 | Charité Berlin | Neuropeptide-expressing vectors and methods for the treatment of epilepsy |
WO2018002081A1 (en) | 2016-06-27 | 2018-01-04 | Aicuris Anti-Infective Cures Gmbh | Hcmv entry inhibitors |
WO2018009553A1 (en) | 2016-07-05 | 2018-01-11 | University Of Massachusetts | Aav2-mediated gene delivery of sfasl as a neuroprotective therapy in glaucoma |
WO2018009894A1 (en) | 2016-07-07 | 2018-01-11 | Iovance Biotherapeutics, Inc. | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof |
WO2018022608A2 (en) | 2016-07-26 | 2018-02-01 | Biomarin Pharmaceutical Inc. | Novel adeno-associated virus capsid proteins |
US11584780B2 (en) | 2016-07-26 | 2023-02-21 | Biomarin Pharmaceutical Inc. | Adeno-associated virus capsid proteins |
WO2018035059A1 (en) | 2016-08-15 | 2018-02-22 | Genzyme Corporation | Methods for detecting aav |
EP3851449A1 (en) | 2016-08-15 | 2021-07-21 | Genzyme Corporation | Methods for detecting aav |
US11525139B2 (en) | 2016-08-23 | 2022-12-13 | Akouos, Inc. | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
US11781145B2 (en) | 2016-08-23 | 2023-10-10 | Akouos, Inc. | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
EP4219724A2 (en) | 2016-08-23 | 2023-08-02 | Akouos, Inc. | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
WO2018049261A1 (en) | 2016-09-09 | 2018-03-15 | Icellhealth Consulting Llc | Oncolytic virus expressing immune checkpoint modulators |
WO2018049248A1 (en) | 2016-09-09 | 2018-03-15 | Icellhealth Consulting Llc | Oncolytic virus equipped with bispecific engager molecules |
WO2018057855A1 (en) | 2016-09-22 | 2018-03-29 | University Of Massachusetts | Aav treatment of huntington's disease |
WO2018060288A1 (en) | 2016-09-29 | 2018-04-05 | Glaxosmithkline Biologicals S.A. | Compositions and methods of treatment of persistent hpv infection |
WO2018069316A2 (en) | 2016-10-10 | 2018-04-19 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
US10415015B2 (en) | 2016-10-31 | 2019-09-17 | Iovance Biotherapeutics, Inc. | Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion |
US11667890B2 (en) | 2016-10-31 | 2023-06-06 | Iovance Biotherapeutics, Inc. | Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion |
WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
WO2018104911A1 (en) | 2016-12-09 | 2018-06-14 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides |
WO2018122088A1 (en) | 2016-12-28 | 2018-07-05 | Transgene Sa | Oncolytic viruses and therapeutic molecules |
US11565979B2 (en) | 2017-01-12 | 2023-01-31 | Pivot Bio, Inc. | Methods and compositions for improving plant traits |
US11739346B2 (en) | 2017-04-05 | 2023-08-29 | University Of Massachusetts | Minigene therapy |
WO2018204694A1 (en) | 2017-05-03 | 2018-11-08 | Biomarin Pharmaceutical Inc. | Improved lentiviruses for transduction of hematopoietic stem cells. |
US11752181B2 (en) | 2017-05-05 | 2023-09-12 | Voyager Therapeutics, Inc. | Compositions and methods of treating Huntington's disease |
US11603542B2 (en) | 2017-05-05 | 2023-03-14 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
WO2018232017A1 (en) | 2017-06-13 | 2018-12-20 | Flagship Pioneering, Inc. | Compositions comprising curons and uses thereof |
US11759506B2 (en) | 2017-06-15 | 2023-09-19 | Voyager Therapeutics, Inc. | AADC polynucleotides for the treatment of Parkinson's disease |
US11773407B2 (en) | 2017-06-26 | 2023-10-03 | Arizona Board Of Regents On Behalf Of Arizona State University | CRISPR logic circuits for safer and controllable gene therapies |
US11890329B2 (en) | 2017-07-06 | 2024-02-06 | The Trustees Of The University Of Pennsylvania | AAV9-mediated gene therapy for treating mucopolysaccharidosis type I |
US11497576B2 (en) | 2017-07-17 | 2022-11-15 | Voyager Therapeutics, Inc. | Trajectory array guide system |
WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | Oncolytic viruses expressing agents targeting metabolic immune modulators |
WO2019028306A2 (en) | 2017-08-03 | 2019-02-07 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
EP3808849A1 (en) | 2017-08-03 | 2021-04-21 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
US11512327B2 (en) | 2017-08-03 | 2022-11-29 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of AAV |
WO2019060726A1 (en) | 2017-09-22 | 2019-03-28 | Genzyme Corporation | Variant rnai |
US11603529B2 (en) | 2017-09-22 | 2023-03-14 | Genzyme Corporation | Variant RNAi |
US11434502B2 (en) | 2017-10-16 | 2022-09-06 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (ALS) |
EP4124658A2 (en) | 2017-10-16 | 2023-02-01 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
WO2019079240A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
US11931375B2 (en) | 2017-10-16 | 2024-03-19 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (ALS) |
US11697801B2 (en) | 2017-12-19 | 2023-07-11 | Akouos, Inc. | AAV-mediated delivery of therapeutic antibodies to the inner ear |
WO2019173434A1 (en) | 2018-03-06 | 2019-09-12 | Voyager Therapeutics, Inc. | Insect cell manufactured partial self-complementary aav genomes |
EP4169576A1 (en) | 2018-03-23 | 2023-04-26 | University of Massachusetts | Gene therapeutics for treating bone disorders |
WO2019191701A1 (en) | 2018-03-30 | 2019-10-03 | The Board Of Trustees Of Leland Stanford Junior University | Novel recombinant adeno-associated virus capsids with enhanced human pancreatic tropism |
US11608510B2 (en) | 2018-03-30 | 2023-03-21 | The Board Of Trustees Of The Leland Stanford Junior University | Recombinant adeno-associated virus capsids with enhanced human pancreatic tropism |
WO2019210137A1 (en) | 2018-04-27 | 2019-10-31 | Voyager Therapeutics, Inc. | Methods for measuring the potency of aadc viral vectors |
WO2019210269A1 (en) | 2018-04-27 | 2019-10-31 | University Of Massachusetts | Aav capsids identified by in vivo library selection |
WO2019217582A1 (en) | 2018-05-08 | 2019-11-14 | Rutgers, The State University Of New Jersey | Aav-compatible laminin-linker polymerization proteins |
US11739345B2 (en) | 2018-05-09 | 2023-08-29 | Biomarin Pharmaceutical Inc. | Methods of treating phenylketonuria |
US11821008B2 (en) | 2018-05-14 | 2023-11-21 | Biomarin Pharmaceutical Inc. | Liver targeting adeno-associated viral vectors |
WO2019222136A2 (en) | 2018-05-14 | 2019-11-21 | Biomarin Pharmaceutical Inc. | Novel liver targeting adeno-associated viral vectors |
WO2019222329A1 (en) | 2018-05-15 | 2019-11-21 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
WO2019222328A1 (en) | 2018-05-15 | 2019-11-21 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of parkinson's disease |
WO2019222444A2 (en) | 2018-05-16 | 2019-11-21 | Voyager Therapeutics, Inc. | Directed evolution |
WO2019222441A1 (en) | 2018-05-16 | 2019-11-21 | Voyager Therapeutics, Inc. | Aav serotypes for brain specific payload delivery |
WO2019239311A1 (en) | 2018-06-12 | 2019-12-19 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides |
WO2020010042A1 (en) | 2018-07-02 | 2020-01-09 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord |
WO2020023612A1 (en) | 2018-07-24 | 2020-01-30 | Voyager Therapeutics, Inc. | Systems and methods for producing gene therapy formulations |
WO2020028816A1 (en) | 2018-08-03 | 2020-02-06 | Genzyme Corporation | Variant rnai against alpha-synuclein |
WO2020072683A1 (en) | 2018-10-02 | 2020-04-09 | Voyager Therapeutics, Inc. | Redirection of tropism of aav capsids |
WO2020072849A1 (en) | 2018-10-04 | 2020-04-09 | Voyager Therapeutics, Inc. | Methods for measuring the titer and potency of viral vector particles |
WO2020077165A1 (en) | 2018-10-12 | 2020-04-16 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
EP4306961A2 (en) | 2018-10-25 | 2024-01-17 | Regeneron Pharmaceuticals, Inc. | Methods for analysis of viral capsid protein composition |
WO2020086893A1 (en) | 2018-10-25 | 2020-04-30 | Regeneron Pharmaceuticals, Inc. | Methods for analysis of viral capsid protein composition |
US11884925B2 (en) | 2018-11-08 | 2024-01-30 | Arizona Board Of Regents On Behalf Of Arizona State University | Synthetic immunomodulation with a CRISPR super-repressor in vivo |
WO2020112967A1 (en) | 2018-11-29 | 2020-06-04 | University Of Massachusetts | Modulation of sptlc1 via recombinant adeno-associated vectors |
US11166996B2 (en) | 2018-12-12 | 2021-11-09 | Flagship Pioneering Innovations V, Inc. | Anellovirus compositions and methods of use |
US11446344B1 (en) | 2018-12-12 | 2022-09-20 | Flagship Pioneering Innovations V, Inc. | Anellovirus compositions and methods of use |
WO2020136232A1 (en) | 2018-12-28 | 2020-07-02 | Transgene Sa | Immunosuppressive m2 protein |
WO2020150556A1 (en) | 2019-01-18 | 2020-07-23 | Voyager Therapeutics, Inc. | Methods and systems for producing aav particles |
WO2020172537A1 (en) | 2019-02-22 | 2020-08-27 | University Of Massachusetts | Oxr1 gene therapy |
WO2020191201A1 (en) | 2019-03-19 | 2020-09-24 | Massachusetts Institute Of Technology | Control of nitrogen fixation in rhizobia that associate with cereals |
WO2020190363A1 (en) | 2019-03-19 | 2020-09-24 | Massachusetts Institute Of Technology | Control of nitrogen fixation in rhizobia that associate with cereals |
WO2020223274A1 (en) | 2019-04-29 | 2020-11-05 | Voyager Therapeutics, Inc. | SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS |
WO2020227515A1 (en) | 2019-05-07 | 2020-11-12 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
WO2020232044A1 (en) | 2019-05-14 | 2020-11-19 | Biomarin Pharmaceutical Inc. | Methods of redosing gene therapy vectors |
WO2021021674A1 (en) | 2019-07-26 | 2021-02-04 | Akouos, Inc. | Methods of treating hearing loss using a secreted target protein |
WO2021030125A1 (en) | 2019-08-09 | 2021-02-18 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
WO2021041485A1 (en) | 2019-08-26 | 2021-03-04 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
WO2021046155A1 (en) | 2019-09-03 | 2021-03-11 | Voyager Therapeutics, Inc. | Vectorized editing of nucleic acids to correct overt mutations |
WO2021050970A1 (en) | 2019-09-13 | 2021-03-18 | Rutgers, The State University Of New Jersey | Aav-compatible laminin-linker polymerization proteins |
WO2021062164A1 (en) | 2019-09-27 | 2021-04-01 | Biomarin Pharmaceutical Inc. | Characterization of gene therapy viral particles using size exclusion chromatography and multi-angle light scattering technologies |
WO2021155137A1 (en) | 2020-01-29 | 2021-08-05 | Genzyme Corporation | Modified adeno-associated viral capsid proteins for ocular gene therapy and methods of use thereof |
WO2021168362A1 (en) | 2020-02-21 | 2021-08-26 | Akouos, Inc. | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
US11807867B2 (en) | 2020-02-21 | 2023-11-07 | Akouos, Inc. | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
WO2021202494A1 (en) | 2020-03-31 | 2021-10-07 | University Of Massachusetts | Aav capsids variants and uses thereof |
WO2021202651A1 (en) | 2020-04-01 | 2021-10-07 | Voyager Therapeutics, Inc. | Redirection of tropism of aav capsids |
WO2021207592A1 (en) | 2020-04-09 | 2021-10-14 | 4Mvac Llc | Use of viral vectors for coronavirus vaccine production |
WO2021211753A1 (en) | 2020-04-15 | 2021-10-21 | Voyager Therapeutics, Inc. | Tau binding compounds |
WO2021214443A1 (en) | 2020-04-20 | 2021-10-28 | Synpromics Limited | Regulatory nucleic acid sequences |
WO2021231538A2 (en) | 2020-05-13 | 2021-11-18 | Akouos, Inc. | Compositions and methods for treating kcnq4-associated hearing loss |
WO2021230987A1 (en) | 2020-05-13 | 2021-11-18 | Voyager Therapeutics, Inc. | Redirection of tropism of aav capsids |
WO2021231567A2 (en) | 2020-05-13 | 2021-11-18 | Akouos, Inc. | Compositions and methods for treating slc26a4-associated hearing loss |
WO2021247995A2 (en) | 2020-06-04 | 2021-12-09 | Voyager Therapeutics, Inc. | Compositions and methods of treating neuropathic pain |
KR20230038496A (en) | 2020-07-13 | 2023-03-20 | 트랜스진 | treatment of immunosuppression |
WO2022013221A1 (en) | 2020-07-13 | 2022-01-20 | Transgene | Treatment of immune depression |
WO2022032153A1 (en) | 2020-08-06 | 2022-02-10 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
WO2022032140A2 (en) | 2020-08-07 | 2022-02-10 | Amicus Therapeutics, Inc. | Vesicle targeting proteins and uses of same |
WO2022051555A2 (en) | 2020-09-03 | 2022-03-10 | Rampart Bioscience, Inc. | Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs |
WO2022049385A1 (en) | 2020-09-04 | 2022-03-10 | Asklepios Biopharmaceutical, Inc. | Regulatory nucleic acid sequences |
WO2022094461A1 (en) | 2020-11-02 | 2022-05-05 | Biomarin Pharmaceutical Inc. | Process for enriching adeno-associated virus |
WO2022119839A1 (en) | 2020-12-01 | 2022-06-09 | Akouos, Inc. | Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms |
WO2022140560A1 (en) | 2020-12-23 | 2022-06-30 | Flagship Pioneering Innovations V, Inc. | In vitro assembly of anellovirus capsids enclosing rna |
WO2022146839A1 (en) | 2020-12-29 | 2022-07-07 | Akouos, Inc. | Compositions and methods for treating clrn1-associated hearing loss and/or vision loss |
WO2022147481A1 (en) | 2020-12-30 | 2022-07-07 | Ansun Biopharma Inc. | Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen |
WO2022147480A1 (en) | 2020-12-30 | 2022-07-07 | Ansun Biopharma, Inc. | Oncolytic virus encoding sialidase and multispecific immune cell engager |
WO2022187473A2 (en) | 2021-03-03 | 2022-09-09 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
WO2022187548A1 (en) | 2021-03-03 | 2022-09-09 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
WO2022214632A1 (en) | 2021-04-07 | 2022-10-13 | Neoplants Sas | Compositions and methods for indoor air remediation |
WO2022235586A1 (en) | 2021-05-03 | 2022-11-10 | Astellas Institute For Regenerative Medicine | Methods of generating mature corneal endothelial cells |
WO2023019203A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Inducible systems for altering gene expression in hypoimmunogenic cells |
WO2023034989A1 (en) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
WO2023034990A1 (en) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
WO2023034996A1 (en) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
WO2023034980A1 (en) | 2021-09-03 | 2023-03-09 | Bomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
WO2023034997A1 (en) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
WO2023034994A1 (en) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
WO2023044483A2 (en) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
WO2023056329A1 (en) | 2021-09-30 | 2023-04-06 | Akouos, Inc. | Compositions and methods for treating kcnq4-associated hearing loss |
WO2023081648A1 (en) | 2021-11-02 | 2023-05-11 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
WO2023091948A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
WO2023107188A1 (en) | 2021-12-10 | 2023-06-15 | Massachusetts Institute Of Technology | Prediction, biosynthesis, and integration as biosensors of molecules with unique light absorbance signatures and their subsequent in-field remote detection using multi or hyper-spectral cameras |
WO2023111580A1 (en) | 2021-12-16 | 2023-06-22 | University Of Dundee | Targeted degradation of alpha-synuclein |
WO2023147374A2 (en) | 2022-01-25 | 2023-08-03 | Voyager Therapeutics, Inc. | Baculovirus expression system |
WO2023150142A1 (en) | 2022-02-02 | 2023-08-10 | Akouos, Inc. | Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms |
WO2023154693A1 (en) | 2022-02-08 | 2023-08-17 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
WO2023152504A1 (en) | 2022-02-10 | 2023-08-17 | University Of Dundee | An affinity-directed phosphatase system for targeted protein dephosphorylation |
WO2023196862A1 (en) | 2022-04-06 | 2023-10-12 | Genzyme Corporation | Targeted gene therapy for dm-1 myotonic dystrophy |
WO2023200843A1 (en) | 2022-04-12 | 2023-10-19 | The Broad Institute, Inc. | Compositions and methods for screening cis regulatory elements |
WO2023201272A1 (en) | 2022-04-12 | 2023-10-19 | Genzyme Corporation | Use of irak4 modulators for gene therapy |
WO2023201274A1 (en) | 2022-04-12 | 2023-10-19 | Genzyme Corporation | Use of an irak4 modulator for gene therapy |
WO2023201273A1 (en) | 2022-04-12 | 2023-10-19 | Genzyme Corporation | Dendritic cell assay for innate immunogenicity to gene therapy agents |
WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
WO2023220729A2 (en) | 2022-05-13 | 2023-11-16 | Flagship Pioneering Innovations Vii, Llc | Double stranded dna compositions and related methods |
WO2023235791A1 (en) | 2022-06-02 | 2023-12-07 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
WO2024006741A1 (en) | 2022-06-28 | 2024-01-04 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
WO2024003353A1 (en) | 2022-07-01 | 2024-01-04 | Transgene | Fusion protein comprising a surfactant-protein-d and a member of the tnfsf |
WO2024011112A1 (en) | 2022-07-06 | 2024-01-11 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
WO2024009280A1 (en) | 2022-07-08 | 2024-01-11 | Baylor College Of Medicine | Integrated stress response inhibitors and methods of using the same |
WO2024054983A1 (en) | 2022-09-08 | 2024-03-14 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
WO2024059739A1 (en) | 2022-09-15 | 2024-03-21 | Voyager Therapeutics, Inc. | Tau binding compounds |
WO2024064863A2 (en) | 2022-09-22 | 2024-03-28 | Biomarin Pharmaceutical Inc. | Treatment of arrhythmogenic cardiomyopathy with aav gene therapy vectors |
WO2024064856A1 (en) | 2022-09-22 | 2024-03-28 | Biomarin Pharmaceutical Inc. | Treatment of cardiomyopathy with aav gene therapy vectors |
EP4345106A1 (en) | 2022-09-30 | 2024-04-03 | Charité - Universitätsmedizin Berlin | Gene therapy vectors for the expression of preprodynorphin variants for the treatment of epilepsy |
WO2024069010A1 (en) | 2022-09-30 | 2024-04-04 | Charité - Universitätsmedizin Berlin | Gene therapy vectors for the expression of preprodynorphin variants for the treatment of epilepsy |
Also Published As
Publication number | Publication date |
---|---|
CA2264482A1 (en) | 1998-03-12 |
JP2001500015A (en) | 2001-01-09 |
AU4183397A (en) | 1998-03-26 |
IL128780A0 (en) | 2000-01-31 |
EP0931158A1 (en) | 1999-07-28 |
AU722624B2 (en) | 2000-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU722624B2 (en) | An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase | |
US6274354B1 (en) | Methods using cre-lox for production of recombinant adeno-associated viruses | |
AU723497C (en) | Method for recombinant adeno-associated virus-directed gene therapy | |
WO1998010086A9 (en) | Methods using cre-lox for production of recombinant adeno-associated viruses | |
US20020037867A1 (en) | Method for recombinant adeno-associated virus-directed gene therapy | |
US6251677B1 (en) | Hybrid adenovirus-AAV virus and methods of use thereof | |
AU695811B2 (en) | Hybrid adenovirus-AAV virus and methods of use thereof | |
US8241622B2 (en) | Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences | |
US20040224411A1 (en) | Recombinant adeno-associated virus production | |
CN1234735A (en) | Method for treating skin pigmentation | |
US20100278791A1 (en) | Adeno-associated virus serotype i nucleic acid sequences, vectors and host cells containing same | |
CN103764831A (en) | Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery | |
CN109321587B (en) | Chimeric antigen receptor T cell interfered by ACAT1 gene | |
CN101463362B (en) | Expression vector for fusion expression of green fluorescent protein, construction method and use thereof | |
AU2021270526B2 (en) | Gene therapy with dysferlin dual vectors | |
MXPA99002215A (en) | Method for recombinant adeno-associated virus-directed gene therapy | |
CN114032217A (en) | Novel coronavirus compound vaccine based on DNA vector and replicative vaccinia virus vector | |
WO2003084977A1 (en) | Gene expression control system and its use in recombinant virus packaging cell lines | |
KR20230085912A (en) | Recombinant adeno-associated viral vector with CD14 promoter and use thereof | |
CN116769811A (en) | TRAIL-secreting engineered macrophages and uses thereof | |
CN114921394A (en) | Recombinant sheep listeria and use method thereof | |
MXPA97003105A (en) | Hybrid adenovirus-virus aav and mi method of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09242742 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 1998 512963 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2264482 Country of ref document: CA Kind code of ref document: A Ref document number: 2264482 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/002216 Country of ref document: MX Ref document number: 1997939829 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997939829 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997939829 Country of ref document: EP |